U.S. patent application number 10/169866 was filed with the patent office on 2004-01-15 for benzimidazole derivatives.
Invention is credited to Matsumoto, Yoshiyuki, Mizuno, Tsuyoshi, Saitou, Hiroshi, Tsuchiya, Naoki.
Application Number | 20040010004 10/169866 |
Document ID | / |
Family ID | 30112181 |
Filed Date | 2004-01-15 |
United States Patent
Application |
20040010004 |
Kind Code |
A1 |
Tsuchiya, Naoki ; et
al. |
January 15, 2004 |
Benzimidazole derivatives
Abstract
A benzimidazole derivative or its medically acceptable salt,
represented by the following formula (1), that is a human chymase
activity inhibitor capable of being applied clinically: 1 wherein,
R.sup.1 and R.sup.2 represent a hydrogen atom, an alkyl group or an
alkoxy group, etc., A represents an alkylene group or an alkenylene
group, E represents --COOR.sup.3, --SO.sub.3R.sup.3, --CONHR.sup.3
or --SO.sub.2NHR.sup.3, etc., G represents an alkylene group, M
represents a single bond or --S(O).sub.m. J represents a
heterocyclic group, and X represents --CH.dbd. or a nitrogen
atom.
Inventors: |
Tsuchiya, Naoki; (Hino-shi,
JP) ; Matsumoto, Yoshiyuki; (Hino-shi, JP) ;
Saitou, Hiroshi; (Hino-shi, JP) ; Mizuno,
Tsuyoshi; (Hino-shi, JP) |
Correspondence
Address: |
SUGHRUE MION, PLLC
2100 PENNSYLVANIA AVENUE, N.W.
WASHINGTON
DC
20037
US
|
Family ID: |
30112181 |
Appl. No.: |
10/169866 |
Filed: |
July 10, 2002 |
PCT Filed: |
January 17, 2001 |
PCT NO: |
PCT/JP01/00271 |
Current U.S.
Class: |
514/292 ;
514/393; 514/394; 546/118; 546/83; 548/302.1; 548/304.4 |
Current CPC
Class: |
C07D 403/06 20130101;
C07D 409/06 20130101 |
Class at
Publication: |
514/292 ;
514/393; 514/394; 546/118; 546/83; 548/302.1; 548/304.4 |
International
Class: |
C07D 491/14; A61K
031/4745; A61K 031/4184 |
Foreign Application Data
Date |
Code |
Application Number |
Jan 17, 2000 |
JP |
2000-007533 |
Claims
1. A benzimidazole derivative or its medically acceptable salt
represented by the following formula (1): 56wherein, R.sup.1 and
R.sup.2 may be the same or different and each independently
represents a hydrogen atom, halogen atom, trihalomethyl group,
cyano group, hydroxyl group, alkyl group having 1-4 carbon atoms,
alkoxy group having 1-4 carbon atoms, or R.sup.1 and R.sup.2
together represent --O--CH.sub.2--O--, --O--CH.sub.2CH.sub.2--O--
or --CH.sub.2CH.sub.2CH.sub.2-- (these groups may be substituted by
one or more alkyl groups having 1-4 carbon atoms); A represents a
substituted or unsubstituted, linear, cyclic or branched alkylene
group or alkenylene group having 1-7 carbon atoms which may be
interrupted by one or more of --O--, --S--, --SO.sub.2-- and
--NR.sup.3-- (where R.sup.3 represents a hydrogen atom or linear or
branched alkyl group having 1-6 carbon atoms); the substituent that
can be possessed by these groups is selected from a halogen atom, a
hydroxyl group, a nitro group, a cyano group, a linear or branched
alkyl group having 1-6 carbon atoms, a linear or branched alkoxy
group having 1-6 carbon atoms (including the case in which two
adjacent groups form an acetal bond, namely including the case in
which the alkyl portions of geminal two alkoxy groups are connected
to form a ring), a linear or branched alkylthio group having 1-6
carbon atoms, a linear or branched alkylsulfonyl group having 1-6
carbon atoms, a linear or branched acyl group having 1-6 carbon
atoms, a linear or branched acylamino group having 1-6 carbon
atoms, a trihalomethyl group, a trihalomethoxy group, a phenyl
group, an oxo group, and a phenoxy group that may be substituted by
one or more halogen atoms; and, one or more of these substituents
may be each independently be bonded to optional positions of the
alkylene or alkenylene group; E represents a --COOR.sup.3, a
--SO.sub.3R.sup.3, a --CONHR.sup.3, a --SO.sub.2NHR.sup.3, a
tetrazole-5-yl group, a 5-oxo-1,2,4-oxadiazole-3-yl group or a
5-oxo-1,2,4-thiadiazole-3-yl group (where R.sup.3 is as defined
above); G represents a substituted or unsubstituted, linear or
branched alkylene group having 1-6 carbon atoms which may be
interrupted by one or more of --O--, --S--, --SO.sub.2-- and
--NR.sup.3-- (where, R.sup.3 is as defined above. Where these atoms
or atomic groups exist, they are not bonded directly to the
benzimidazole ring.); and, the substituent that can be possessed by
said alkylene group is selected from a halogen atom, a hydroxyl
group, a nitro group, a cyano group, a linear or branched alkyl
group having 1-6 carbon atoms, a linear or branched alkoxy group
having 1-6 carbon atoms (including the case in which two adjacent
groups form an acetal bond), a trihalomethyl group, a
trihalomethoxy group, a phenyl group, an oxo group; M represents a
single bond or --S(O)--, where m is an integer of 0-2; J represents
a substituted or unsubstituted heterocyclic group having 4-10
carbon atoms and containing one or more hetero atoms selected from
the group consisting of an oxygen atom, a nitrogen atom and a
sulfur atom on its ring, with the proviso that an imidazole ring is
excluded; the substituent that can be possessed by said heteroaryl
group is selected from a halogen atom, a hydroxyl group, a nitro
group, a cyano group, a linear or branched alkyl group having 1-6
carbon atoms, a linear or branched alkoxy group having 1-6 carbon
atoms (including the case in which two adjacent groups form an
acetal bond), a linear or branched alkylthio group having 1-6
carbon atoms, a linear or branched alkylsulfonyl group having 1-6
carbon atoms, a linear or branched acyl group having 1-6 carbon
atoms, a linear or branched acylamino group having 1-6 carbon
atoms, a substituted or non-substituted anilide group, a
trihalomethyl group, a trihalomethoxy group, a phenyl group, an oxo
group, a COOR.sup.3 group, and a phenoxy group that may be
substituted by one or more halogen atoms; and, one or more of these
substituents may be substituted at optional positions on the ring;
and, X represents a methine group (--CH.dbd.) or nitrogen atom.
2. A benzimidazole derivative or its medically acceptable salt
according to claim 1 wherein, in said formula (1), A represents a
substituted or unsubstituted, linear, cyclic or branched alkylene
group having 1-7 carbon atoms (and may be interrupted by one or
more of --O--, --S--, --SO.sub.2-- and --NR.sup.3--).
3. A benzimidazole derivative or its medically acceptable salt
according to claim 1 or 2 wherein, in said formula (1), M
represents S.
4. A benzimidazole derivative or its medically acceptable salt
according to claim 1 or 2 wherein, in said formula (1), M
represents SO.sub.2.
5. A benzimidazole derivative or its medically acceptable salt
according to claim 1 or 2 wherein, in said formula (1), M
represents SO.
6. A benzimidazole derivative or its medically acceptable salt
according to claim 1 or 2 wherein, in said formula (1), M
represents a single bond.
7. A benzimidazole derivative or its medically acceptable salt
according to any one of claims 1 to 6, wherein, in said formula
(1), J represents a substituted or unsubstituted heterocyclic group
having 7-10 carbon atoms and containing one or more hetero atoms
selected from the group consisting of an oxygen atom, a nitrogen
atom and a sulfur atom on its ring.
8. A benzimidazole derivative or its medically acceptable salt
according to any one of claims 1 to 7, wherein, in said formula
(1), G represents --CH.sub.2--, --CH.sub.2CH.sub.2--,
--CH.sub.2CO--, --CH.sub.2CH.sub.2O--, --CH.sub.2CONH--, --CO--,
--SO.sub.2--, --CH.sub.2SO.sub.2--, --CH.sub.2S-- or
--CH.sub.2CH.sub.2S-- (and these divalent groups are bonded on the
left hand side to position 1 of the benzimidazole ring while on the
right hand side to J).
9. A benzimidazole derivative or its medically acceptable salt
according to any one of claim 1 to 8, wherein, in said formula (1),
R.sup.1 and R.sup.2 may be the same or different and each
independently represents a hydrogen atom, a halogen atom, an alkyl
group having 1-4 carbon atoms, an alkoxy group having 1-4 carbon
atoms, a trihalomethyl group, a cyano group or a hydroxyl
group.
10. A benzimidazole derivative or its medically acceptable salt
according to any one of claims 1 to 9, wherein, in said formula
(1), E represents --COOH or a tetrazole-5-yl group.
11. A benzimidazole derivative or its medically acceptable salt
according to any one of claims 1 to 10, wherein, in said formula
(1), X represents --CH.dbd..
12. A human chymase inhibitor containing as its active ingredient
at least one benzimidazole derivative or its medically acceptable
salt according to claim 1.
13. A therapeutic agent, for diseases primarily caused by the
appearance of human chymase activity, containing as its active
ingredient at least one benzimidazole derivative or its medically
acceptable salt according to claim 1.
14. A pharmaceutical composition comprising at least one
benzimidazole or its medically acceptable salt according to claim
1, and a pharmaceutically acceptable carrier.
15. A pharmaceutical composition according to claim 14, which is a
preventive agent and/or therapeutic agent for a disease.
16. A pharmaceutical composition according to claim 15, wherein
said disease is an inflammatory disease, an allergic disease, a
respiratory disease, a cardiovascular disease or a bone or
cartilage metabolic disease.
Description
TECHNICAL FIELD
[0001] The present invention relates to a benzimidazole derivative,
and more particularly, to a benzimidazole derivative useful as an
inhibitor of human chymase activity.
BACKGROUND ART
[0002] Chymase is a neutral protease present in mast cell granules,
and is intimately involved in various biological reactions
participated in by mast cells. For example, chymase has been
reported to have various actions, including the promotion of
degranulation from mast cells, activation of Interleukin-1.beta.
(IL-10), activation of matrix protease, decomposition of
fibronectin and type IV collagen, promotion of the liberation of
transforming growth factor-.beta. (TGF-.beta.), activation of
substance P and vasoactive intestinal polypeptide (VIP), conversion
from angiotensin I (Ang I) to angiotensin II (Ang II), and
conversion of endothelin.
[0003] On the basis of the above, inhibitors of said chymase
activity are considered to be promising as preventive and/or
therapeutic agents against respiratory diseases such as bronchial
asthma, inflammatory and allergic diseases such as allergic
rhinitis, atopic dermatitis and urticaria, cardiovascular diseases
such as sclerosing vascular lesions, vasoconstriction, peripheral
circulatory disorders, renal insufficiency and cardiac
insufficiency, and bone and cartilage metabolic diseases such as
rheumatoid arthritis and osteoarthritis.
[0004] Although known examples of chymase activity inhibitors of
the prior art include a triazine derivative (Japanese Unexamined
Patent Publication No. 8-208654), hydantoin derivative (Japanese
Unexamined Patent Publication No. 9-31061), imidazolidine
derivative (International Publication No. WO96/04248), quinazoline
derivative (International Publication No. WO97/11941), heterocyclic
amide derivative (International Patent Publication No. WO96/33974),
cefam compound (Japanese Unexamined Patent Publication No.
10-087493), phenol derivative (Japanese Unexamined Publication No.
10-087567), heterocyclic amide compound (International Publication
No. WO98/18794), acetoamide derivative (International Publication
No. WO98/09949), heterocyclic amide compound (Japanese Unexamined
Publication No. 10-007661), acid anhydride derivative (Japanese
Unexamined Patent Publication No. 11-049739), heterocyclic amide
compound (International Publication No. WO99/32459) and acetoamide
derivative (International Publication No. WO99/41277), these
compounds and the compound of the present invention are completely
different structurally.
[0005] The chymase inhibitor compounds disclosed thus far have
lacked usefulness as a result of having inadequate activity or
being structurally unstable. However, the compound of the present
invention has extremely high activity and demonstrates superior
kinetics in the blood, making it highly useful as a drug.
[0006] On the other hand, an example of a technology related to the
compound of the present invention is described in the specification
of U.S. Pat. No. 5,124,336. A benzimidazole derivative is described
in said specification as a compound that has thromboxane receptor
antagonistic activity. However, the compound described in said
specification is not disclosed as having a heteroaryl group
substituted in the benzimidazole skeleton, and there is also no
description of human chymase activity of said compound. In
addition, although a benzimidazole compound is also described as an
antitumor agent in Japanese Unexamined Patent Publication No.
01-265089, there is no mention of human chymase inhibitory
activity.
DISCLOSURE OF THE INVENTION
[0007] The object of the present invention is to provide a novel
compound capable of being a human chymase activity inhibitor that
can be applied clinically.
[0008] As a result of repeated and earnest research to achieve the
above object, the inventors of the present invention found a
benzimidazole derivative or its medically acceptable salt,
represented by the following formula (1), that has a structure that
is completely different from known compounds, thereby leading to
completion of the present invention: 2
[0009] wherein, R.sup.1 and R.sup.2 may be the same or different
and each independently represents a hydrogen atom, a halogen atom,
a trihalomethyl group, a cyano group, a hydroxyl group, an alkyl
group having 1-4 carbon atoms, an alkoxy group having 1-4 carbon
atoms, or R1and R.sup.2 together represent --O--CH.sub.2--O--,
--O--CH.sub.2CH.sub.2--O-- or --CH.sub.2CH.sub.2CH.sub.2-- (these
groups may be substituted by one or more alkyl groups having 1-4
carbon atoms);
[0010] A represents a substituted or unsubstituted, linear, cyclic
or branched alkylene or alkenylene group having 1-7 carbon atoms
which may be interrupted by one or more of --O--, --S--,
--SO.sub.2-- and --NR.sup.3-- (where R.sup.3 represents a hydrogen
atom or linear or branched alkyl group having 1-6 carbon atoms);
the substituent that can be possessed by these groups is selected
from a halogen atom, hydroxyl group, nitro group, cyano group,
linear or branched alkyl group having 1-6 carbon atoms, linear or
branched alkoxy group having 1-6 carbon atoms (including the case
in which two adjacent groups form an acetal bond, namely including
the case in which the alkyl portions of geminal two alkoxy groups
are connected to form a ring), a linear or branched alkylthio group
having 1-6 carbon atoms, a linear or branched alkylsulfonyl group
having 1-6 carbon atoms, a linear or branched acyl group having 1-6
carbon atoms, a linear or branched acylamino group having 1-6
carbon atoms, a trihalomethyl group, a trihalomethoxy group, a
phenyl group, an oxo group, and a phenoxy group that may be
substituted by one or more halogen atoms; and, one or more of these
substituents may each independently be bonded to optional positions
of the alkylene or alkenylene group;
[0011] E represents a --COOR.sup.3, --SO.sub.3R.sup.3,
--CONHR.sup.3, --SO.sub.2NHR.sup.3, tetrazole-5-yl group, a
5-oxo-1,2,4-oxadiazole-3-yl group or a 5-oxo-1,2,4-thiadiazole-3-yl
group (where R.sup.3 is as defined above);
[0012] G represents a substituted or unsubstituted, linear or
branched alkylene group having 1-6 carbon atoms which may be
interrupted by one or more of --O--, --S--, --SO.sub.2-- and
--NR.sup.3-- (where, R.sup.3 is as defined above. Where these atoms
or atomic groups exist, they are not bonded directly to the
benzimidazole ring.); and, the substituent that can be possessed by
said alkylene group is selected from a halogen atom, a hydroxyl
group, a nitro group, a cyano group, a linear or branched alkyl
group having 1-6 carbon atoms, a linear or branched alkoxy group
having 1-6 carbon atoms (including the case in which two adjacent
groups form an acetal bond), a trihalomethyl group, a
trihalomethoxy group, a phenyl group, and an oxo group;
[0013] M represents a single bond or --S(O).sub.m--, where m is an
integer of 0-2;
[0014] J represents a substituted or unsubstituted heterocyclic
group having 4-10 carbon atoms and containing one or more hetero
atoms selected from the group consisting of an oxygen atom, a
nitrogen atom and a sulfur atom on its ring, with the proviso that
an imidazole ring is excluded; the substituent that can be
possessed by said aromatic hetetrocyclic group is selected from a
halogen atom, a hydroxyl group, a nitro group, a cyano group, a
linear or branched alkyl group having 1-6 carbon atoms, a linear or
branched alkoxy group having 1-6 carbon atoms (including the case
in which two adjacent groups form an acetal bond), a linear or
branched alkylthio group having 1-6 carbon atoms, a linear or
branched alkylsulfonyl group having 1-6 carbon atoms, a linear or
branched acyl group having 1-6 carbon atoms, a linear or branched
acylamino group having 1-6 carbon atoms, a substituted or
unsubstituted anilide group, a trihalomethyl group, a
trihalomethoxy group, a phenyl group, an oxo group, a COOR.sup.3
group, and a phenoxy group that may be substituted by one or more
halogen atoms; and, one or more of these substitutents may be
substituted at optional positions on the ring; and,
[0015] X represents a methine group (--CH.dbd.) or nitrogen
atom.
BEST MODE FOR CARRYING OUT THE INVENTION
[0016] The substituents in the compound of the present invention
represented by the above formula (1) are as indicated below.
[0017] R.sup.1 and R.sup.2 may be the same or different and each
independently represents a hydrogen atom, a halogen atom,
trihalomethyl group, a cyano group, a hydroxyl group, an alkyl
group having 1-4 carbon atoms, an alkoxy group having 1-4 carbon
atoms. Alternatively, R.sup.1 and R.sup.2 together represent
--O--CH.sub.2--O--, --O--CH.sub.2CH.sub.2--O-- or
--CH.sub.2CH.sub.2CH.sub.2--, and in this case, these groups may be
substituted by one or more alkyl groups having 1-4 carbon
atoms.
[0018] Specific examples of the alkyl groups having 1-4 carbon
atoms as R.sup.1 and R.sup.2 include a methyl group, an ethyl
group, an n- or i-propyl group and an n-, i-, s- or t-butyl group.
A preferable example is a methyl group. Specific examples of alkoxy
groups having 1-4 carbon atoms include a methoxy group, an ethoxy
group, an n- or i-propoxy group and an n-, i-, s- or t-butoxy
group.
[0019] Preferable examples of R.sup.1 and R.sup.2 include a
hydrogen atom, a halogen atom, a trihalomethyl group, a cyano
group, a hydroxyl group, an alkyl group having 1-4 carbon atoms and
an alkoxy group having 1-4 carbon atoms. More preferable examples
include a hydrogen atom, a halogen atom, a trihalomethyl group, a
cyano group, an alkyl group having 1-4 carbon atoms and an alkoxy
group having 1-4 carbon atoms, still more preferable examples
include a hydrogen atom, chlorine atom, a fluorine atom, a
trifluoromethyl group, methyl group, a methoxy group and an ethoxy
group, while particularly preferable examples include a hydrogen
atom, a methyl group and a methoxy group.
[0020] A represents a substituted or unsubstituted, linear, cyclic
or branched alkylene or alkenylene group having 1-7 carbon atoms.
Examples of the unsubstituted, linear, cyclic or branched alkylene
group having 1-7 carbon atoms include a methylene group, an
ethylene group, an n- or i-propylene group, a 2,2-dimethylpropylene
group, an n-, i- or t-butylene group, a 1,1-dimethylbutylene group,
an n-pentylene group and a cyclohexylene group. More preferable
examples include an ethylene group, an n-propylene group, a
2,2-dimethylpropylene group and an n- or t-butylene group. Still
more preferable examples include an n-propylene group and a
2,2-dimethylpropylene group. A particularly preferable example is
an n-propylene group. Examples of the unsubstituted linear or
branched alkenylene group having 1-7 carbon atoms include a
vinylene group, a propenylene group, a butenylene group and a
pentenylene group.
[0021] Although said alkylene group or alkenylene group may be
interrupted by one or more of --O--, --S--, --SO.sub.2-- and
--NR.sup.3-- (where R3 represents a hydrogen atom or linear or
branched alkyl group having 1-6 carbon atoms), these atoms or
atomic groups are not bonded directly to M. Specific examples
include interrupted ethylene groups, n-propylene groups or n- or
t-butylene groups. More specific examples include
--CH.sub.2OCH.sub.2--, --CH.sub.2OCH.sub.2CH.sub.2--,
--CH.sub.2SCH.sub.2--, --CH.sub.2SCH.sub.2CH.sub.2--,
--CH.sub.2SO.sub.2CH.sub.2--, --CH.sub.2SO.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2NR.sup.4CH.sub.2-- and
--CH.sub.2NR.sup.4CH.sub.2CH.sub.2--. Preferable examples include
--CH.sub.2OCH.sub.2--, --CH.sub.2SCH.sub.2-- and
--CH.sub.2SO.sub.2CH.sub.2--.
[0022] The substituent groups that can be possessed by said
alkylene group is selected from a halogen atom, a hydroxyl group, a
nitro group, a cyano group, a linear or branched alkyl group having
1-6 carbon atoms, a linear or branched alkoxy group having 1-6
carbon atoms (including the case in which two adjacent groups form
an acetal bond), a linear or branched alkylthio group having 1-6
carbon atoms, a linear or branched alkylsulfonyl group having 1-6
carbon atoms, linear or branched acyl group having 1-6 carbon
atoms, a linear or branched acylamino group having 1-6 carbon
atoms, a trihalomethyl group, a trihalomethoxy group, a phenyl
group, an oxo group, and a phenoxy group that may be substituted by
one or more halogen atoms. One or more of these substituents may
each be independently bonded to optional positions of the alkylene
group or alkenylene group.
[0023] Examples of the halogen atom include a fluorine atom, a
chlorine atom, a bromine atom and an iodine atom. Preferable
examples are a fluorine atom and a chlorine atom.
[0024] Specific examples of the linear or branched alkyl group
having 1-6 carbon atoms include a methyl group, an ethyl group, an
n- or i-propyl group and an n-, i-, s- or t-butyl group, while
preferable examples are a methyl group and an ethyl group. A more
preferable example is a methyl group.
[0025] Specific examples of the linear or branched alkoxy group
having 1-6 carbon atoms include a methoxy group, an ethoxy group,
an n- or i-propoxy group and an n-, i-, s- or t-butoxy group, while
preferable examples are a methoxy group and an ethoxy group. A more
preferable example is a methoxy group.
[0026] Specific examples of the linear or branched alkylthio group
having 1-6 carbon atoms include a methylthio group, an ethylthio
group, an n- or i-propylthio group, and an n-, i-, s- or
t-butylthio group, and preferable examples are a methylthio group
and an ethylthio group. A more preferable example is a methylthio
group.
[0027] Specific examples of the linear or branched alkylsulfonyl
group having 1-6 carbon atoms include a methylsulfonyl group, an
ethylsulfonyl group, an n- or i-propylsulfonyl group and an n-, i-,
s- or t-butylsulfonyl group, and preferable examples are a
methylsulfonyl group and an ethylsulfonyl group. A more preferable
example is a methylsulfonyl group.
[0028] Examples of the linear or branched acyl group having 1-6
carbon atoms include an acetyl group, an ethylcarbonyl group, an n-
or i-propylcarbonyl group and an n-, i-, s- or t-butylcarbonyl
group, and preferable examples are an acetyl group and an
ethylcarbonyl group. A more preferable example is an acetyl
group.
[0029] Specific examples of the linear or branched acylamino group
having 1-6 carbon atoms include an acetylamino group, an
ethylcarbonylamino group, an n- or i-propylcarbonylamino group and
an n-, i-, s- or t-butylcarbonylamino group, and preferable
examples are an acetylamino group and an ethylcarbonylamino group.
A more preferable example is an acetylamino group.
[0030] Specific examples of the trihalomethyl group are a
trifluoromethyl group, a tribromomethyl group and a trichloromethyl
group. A preferable example is a trifluoromethyl group.
[0031] In particular, A is preferably a substituted or
unsubstituted, linear, cyclic or branched alkylene group having 1-7
carbon atoms {although it may be interrupted by one or more of
--O--, --S--, --SO.sub.2-- and --NR.sup.3-- (where NR.sup.3 is as
defined above), these atoms or atomic groups not being bonded
directly to M}. Preferable examples include --CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2--, --CH.sub.2C(.dbd.O)CH.sub.2--,
--CH.sub.2OCH.sub.2--, --CH.sub.2SCH.sub.2--,
--CH.sub.2S(.dbd.O)CH.sub.2--, --CH.sub.2CF.sub.2CH.sub.2--,
--CH.sub.2SO.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2C(CH.sub.3).sub.2CH.sub.2- --,
--CH.sub.2SO.sub.2CH.sub.2CH.sub.2--, --CH.sub.2C
(.dbd.O)CH.sub.2CH.sub.2--, --CH.sub.2C(.dbd.O)
(CH.sub.3).sub.2CH.sub.2-- -, and
--CH.sub.2C(.dbd.O)C(.dbd.O)CH.sub.2--. More preferable examples
are --CH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2C(.dbd.O)CH.sub.2--, --CH.sub.2OCH.sub.2--,
CH.sub.2SCH.sub.2--, --CH.sub.2S(.dbd.O)CH.sub.2--,
--CH.sub.2CF.sub.2CH.sub.2--, --CH.sub.2SO.sub.2CH.sub.2-- and
--CH.sub.2C(CH.sub.3).sub.2CH.sub.2--. Still more preferable
examples are --CH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2-- and
--CH.sub.2C(CH.sub.3).sub.2CH.sub.2--. A particularly preferable
example is --CH.sub.2CH.sub.2CH.sub.2--
[0032] E represents a --COOR.sup.3, --SO.sub.3R.sup.3,
--CONHR.sup.3, --SO.sub.2NHR.sup.3, tetrazole-5-yl,
5-oxo-1,2,4-oxadiazole-3-yl or 5-oxo-1,2,4-thiadiazole-3-yl group
(where, R.sup.3 represents a hydrogen atom or linear or branched
alkyl group having 1-6 carbon atoms).
[0033] Examples of R.sup.3 include a hydrogen atom, a methyl group,
an ethyl group, an n- or i-propyl group and an n-, i-, s- or
t-butyl group. Preferable examples are a hydrogen atom, a methyl
group and an ethyl group. A particularly preferable example is a
hydrogen atom.
[0034] In particular, preferable examples of E are --COOR.sup.3,
--SO.sub.3R.sup.3, and tetrazole-5-yl groups. A more preferable
example is a --COOR.sup.3 group. A particularly preferable example
is a --COOH group.
[0035] G represents a substituted or unsubstituted, linear or
branched alkylene group having 1-6 carbon atoms which may be
interrupted by one or more of --O--, --S--, --SO.sub.2-- and
--NR.sup.3--. Here, R.sup.3 is as defined above. In addition, in
the case of containing these hetero atoms or atomic groups, they
are not directly bonded to the benzimidazole ring. The substituent
that can be possessed by the alkylene group is selected from a
halogen atom, a hydroxyl group, a nitro group, a cyano group, a
linear or branched alkyl group having 1-6 carbon atoms, a linear or
branched alkoxy group having 1-6 carbon atoms (including the case
in which two adjacent groups form an acetal bond), a trihalomethyl
group, a trihalomethoxy group, a phenyl group and an oxo group.
Specific examples of G include --CH.sub.2--, --CH.sub.2CH.sub.2--,
--CH.sub.2CO--, --CH.sub.2CH.sub.2O--, --CH.sub.2CONH--, --CO--,
--SO.sub.2--, --CH.sub.2SO.sub.2--, --CH.sub.2S-- and
--CH.sub.2CH.sub.2S--, while preferable examples are --CH.sub.2--,
--CH.sub.2CH.sub.2--, --CH.sub.2CO-- and --CH.sub.2CH.sub.2O--.
More preferable examples are --CH.sub.2-- and --CH.sub.2CH.sub.2--,
and a particularly preferable example is --CH.sub.2--. These groups
are bonded on the left hand side to position 1 (N atom) of the
benzimidazole ring, while on the right hand side to J.
[0036] M represents a single bond or --S(O).sub.m--, where m
represents an integer of 0-2. Preferable examples of M are --S--
and --SO.sub.2--. A particularly preferable example is --S--.
[0037] J represents a substituted or unsubstituted heterocyclic
group having 4-10 carbon atoms and containing one or more hetero
atoms selected from the group consisting of an oxygen atom, a
nitrogen atom and a sulfur atom on its ring. However, an imidazole
ring is excluded. In addition, J is limited to that which can be
chemically synthesized.
[0038] Specific examples of the unsubstituted heterocyclic groups
having 4-10 carbon atoms and containing one or more hetero atoms on
its ring selected from the group consisting of an oxygen atom, a
nitrogen atom and a sulfur atom include a pyridyl group, a furyl
group, a thienyl group, a thiazolyl group, a pyrimidinyl group, an
oxazolyl group, an isooxazolyl group, a benzofuryl group, a
benzimidazolyl group, a quinolyl group, an isoquinolyl group, a
quinoxalinyl group, a benzoxadiazolyl group, a benzothiaziazolyl
group, an indolyl group, a benzothiazolyl group, a benzothienyl
group and a benzoisooxazolyl group. A preferable example is a
bicyclic heterocyclic ring. More preferable examples are a
benzofuryl group, a benzoimidazolyl group, a quinolyl group, an
isoquinolyl group, a quinoxalinyl group, a benzoxadiazolyl group, a
benzothiazolyl group, an indolyl group, a benzothiazolyl group, a
benzothienyl group and a benzoisooxazolyl group, while a
particularly preferable example is a benzothienyl group or an
indolyl group.
[0039] The substituent groups that can be possessed by the aromatic
heterocyclic group is selected from a halogen atom, a hydroxyl
group, a nitro group, a cyano group, a linear or branched alkyl
group having 1-6 carbon atoms, a linear or branched alkoxy group
having 1-6 carbon atoms (including the case in which two adjacent
groups form an acetal bond), a linear or branched alkylthio group
having 1-6 carbon atoms, a linear or branched alkylsulfonyl group
having 1-6 carbon atoms, a linear or branched acyl group having 1-6
carbon atoms, a linear or branched acylamino group having 1-6
carbon atoms, a substituted or unsubstituted anilide group, a
trihalomethyl group, a trihalomethoxy group, a phenyl group, and a
phenoxy group that may be substituted by one or more halogen atoms.
One or more of these substituents groups may each independently be
bonded to optional positions of the ring.
[0040] Examples of the halogen atom are a fluorine atom, a chlorine
atom, a bromine atom and an iodine atom. Preferable examples are a
fluorine atom and a chlorine atom.
[0041] Specific examples of the linear or branched alkyl groups
having 1-6 carbon atoms include a methyl group, an ethyl group, an
n- or i-propyl group and an n-, i-, s- or t-butyl group, and
preferable examples are a methyl group and an ethyl group. A more
preferable example is a methyl group.
[0042] Specific examples of the linear or branched alkoxy groups
having 1-6 carbon atoms include a methoxy group, an ethoxy group,
an n- or i-propyloxy group, an n-, i-, s- or t-butyloxy group and a
methylenedioxy group, and preferable examples are a methoxy group
and an ethoxy group. A more preferable example is a methoxy
group.
[0043] Specific examples of the linear or branched alkylthio group
having 1-6 carbon atoms include a methylthio group, an ethylthio
group, an n- or i-propylthio group and an n-, i-, s- or t-butylthio
group, and preferable examples are a methylthio group and an
ethylthio group. A more preferable example is a methylthio
group.
[0044] Specific examples of the linear or branched alkylsulfonyl
group having 1-6 carbon atoms include a methylsulfonyl group, an
ethylsulfonyl group, an n- or i-propylsulfonyl group and an n-, i-,
s- or t-butylsulfonyl group, and preferable examples are a
methylsulfonyl group and an ethylsulfonyl group. A more preferable
example is a methylsulfonyl group.
[0045] Specific examples of the linear or branched acyl group
having 1-6 carbon atoms include an acetyl group, an ethylcarbonyl
group, an n- or i-propylcarbonyl group and an n-, i-, s- or
t-butylcarbonyl group, and preferable examples are an acetyl group
and an ethylcarbonyl group. A more preferable example is an acetyl
group.
[0046] Specific examples of the linear or branched acylamino group
having 1-6 carbon atoms include an acetylamino group, an
ethylcarbonylamino group, an n- or i-propylcarbonylamino group and
an n-, i-, s- or t-butylcarbonylamino group, and preferable
examples are an acetylamino group and an ethylcarbonylamino group.
A more preferable example is an acetylamino group.
[0047] Specific examples of the trihalomethyl group include a
trifluoromethyl group, a tribromomethyl group and a trichloromethyl
group.
[0048] X represents a --CH.dbd. group or nitrogen atom, and a
preferable example is a --CH.dbd. group.
[0049] Preferable examples of the compounds represented by the
above formula (1) include various groups of compounds composed by
combining each of the groups previously described as preferable
examples. Although there is no intention of limiting these groups,
those described in the following table are particularly preferable.
In particular, preferable examples of those compounds in the table
include compound Nos. 34, 38, 39, 41, 42, 52, 54, 56, 58, 59, 63,
135, 137, 148, 152, 154, 244, 340, 436, 514, 519, 521, 532, 534,
536, 538, 615, 628, 1112 and 1114. Furthermore, A1 through A3 and
J1 through J32 in the following table are groups represented with
the following formulas. In the formulas, although E, G, M, m and X
are as defined above, they are described hereinbelow using
representative examples, namely E is COOH, G is CH.sub.2, M is S (m
being 0) or a single bond (indicated with "-" in the table) and X
is --CH.dbd.. However, it is not intended that the present
invention is limited to these compounds. 34567
1 Compound No. R.sub.1 R.sub.2 A J M 1 H H A1 J1 S 2 H H A1 J2 S 3
H H A1 J3 S 4 H H A1 J4 S 5 H H A1 J5 S 6 H H A1 J6 S 7 H H A1 J7 S
8 H H A1 J8 S 9 H H A1 J9 S 10 H H A1 J10 S 11 H H A1 J11 S 12 H H
A1 J12 S 13 H H A1 J13 S 14 H H A1 J14 S 15 H H A1 J15 S 16 H H A1
J16 S 17 H H A1 J17 S 18 H H A1 J18 S 19 H H A1 J19 S 20 H H A1 J20
S 21 H H A1 J21 S 22 H H A1 J22 S 23 H H A1 J23 S 24 H H A1 J24 S
25 H H A1 J25 S 26 H H A1 J26 S 27 H H A1 J27 S 28 H H A1 J28 S 29
H H A1 J29 S 30 H H A1 J30 S 31 H H A1 J31 S 32 H H A1 J32 S 33 H H
A2 J1 S 34 H H A2 J2 S 35 H H A2 J3 S 36 H H A2 J4 S 37 H H A2 J5 S
38 H H A2 J6 S 39 H H A2 J7 S 40 H H A2 J8 S 41 H H A2 J9 S 42 H H
A2 J10 S 43 H H A2 J11 S 44 H H A2 J12 S 45 H H A2 J13 S 46 H H A2
J14 S 47 H H A2 J15 S 48 H H A2 J16 S 49 H H A2 J17 S 50 H H A2 J18
S 51 H H A2 J19 S 52 H H A2 J20 S 53 H H A2 J21 S 54 H H A2 J22 S
55 H H A2 J23 S 56 H H A2 J24 S 57 H H A2 J25 S 58 H H A2 J26 S 59
H H A2 J27 S 60 H H A2 J28 S 61 H H A2 J29 S 62 H H A2 J30 S 63 H H
A2 J31 S 64 H H A2 J32 S 65 H H A3 J1 S 66 H H A3 J2 S 67 H H A3 J3
S 68 H H A3 J4 S 69 H H A3 J5 S 70 H H A3 J6 S 71 H H A3 J7 S 72 H
H A3 J8 S 73 H H A3 J9 S 74 H H A3 J10 S 75 H H A3 J11 S 76 H H A3
J12 S 77 H H A3 J13 S 78 H H A3 J14 S 79 H H A3 J15 S 80 H H A3 J16
S 81 H H A3 J17 S 82 H H A3 J18 S 83 H H A3 J19 S 84 H H A3 J20 S
85 H H A3 J21 S 86 H H A3 J22 S 87 H H A3 J23 S 88 H H A3 J24 S 89
H H A3 J25 S 90 H H A3 J26 S 91 H H A3 J27 S 92 H H A3 J28 S 93 H H
A3 J29 S 94 H H A3 J30 S 95 H H A3 J31 S 96 H H A3 J32 S 97 MeO H
A1 J1 S 98 MeO H A1 J2 S 99 MeO H A1 J3 S 100 MeO H A1 J4 S 101 MeO
H A1 J5 S 102 MeO H A1 J6 S 103 MeO H A1 J7 S 104 MeO H A1 J8 S 105
MeO H A1 J9 S 106 MeO H A1 J10 S 107 MeO H A1 J11 S 108 MeO H A1
J12 S 109 MeO H A1 J13 S 110 MeO H A1 J14 S 111 MeO H A1 J15 S 112
MeO H A1 J16 S 113 MeO H A1 J17 S 114 MeO H A1 J18 S 115 MeO H A1
J19 S 116 MeO H A1 J20 S 117 MeO H A1 J21 S 118 MeO H A1 J22 S 119
MeO H A1 J23 S 120 MeO H A1 J24 S 121 MeO H A1 J25 S 122 MeO H A1
J26 S 123 MeO H A1 J27 S 124 MeO H A1 J28 S 125 MeO H A1 J29 S 126
MeO H A1 J30 S 127 MeO H A1 J31 S 128 MeO H A1 J32 S 129 MeO H A2
J1 S 130 MeO H A2 J2 S 131 MeO H A2 J3 S 132 MeO H A2 J4 S 133 MeO
H A2 J5 S 134 MeO H A2 J6 S 135 MeO H A2 J7 S 136 MeO H A2 J8 S 137
MeO H A2 J9 S 138 MeO H A2 J10 S 139 MeO H A2 J11 S 140 MeO H A2
J12 S 141 MeO H A2 J13 S 142 MeO H A2 J14 S 143 MeO H A2 J15 S 144
MeO H A2 J16 S 145 MeO H A2 J17 S 146 MeO H A2 J18 S 147 MeO H A2
J19 S 148 MeO H A2 J20 S 149 MeO H A2 J21 S 150 MeO H A2 J22 S 151
MeO H A2 J23 S 152 MeO H A2 J24 S 153 MeO H A2 J25 S 154 MeO H A2
J26 S 155 MeO H A2 J27 S 156 MeO H A2 J28 S 157 MeO H A2 J29 S 158
MeO H A2 J30 S 159 MeO H A2 J31 S 160 MeO H A2 J32 S 161 MeO H A3
J1 S 162 MeO H A3 J2 S 163 MeO H A3 J3 S 164 MeO H A3 J4 S 165 MeO
H A3 J5 S 166 MeO H A3 J6 S 167 MeO H A3 J7 S 168 MeO H A3 J8 S 169
MeO H A3 J9 S 170 MeO H A3 J10 S 171 MeO H A3 J11 S 172 MeO H A3
J12 S 173 MeO H A3 J13 S 174 MeO H A3 J14 S 175 MeO H A3 J15 S 176
MeO H A3 J16 S 177 MeO H A3 J17 S 178 MeO H A3 J18 S 179 MeO H A3
J19 S 180 MeO H A3 J20 S 181 MeO H A3 J21 S 182 MeO H A3 J22 S 183
MeO H A3 J23 S 184 MeO H A3 J24 S 185 MeO H A3 J25 S 186 MeO H A3
J26 S 187 MeO H A3 J27 S 188 MeO H A3 J28 S 189 MeO H A3 J29 S 190
MeO H A3 J30 S 191 MeO H A3 J31 S 192 MeO H A3 J32 S 193 CN H A1 J1
S 194 CN H A1 J2 S 195 CN H A1 J3 S 196 CN H A1 J4 S 197 CN H A1 J5
S 198 CN H A1 J6 S 199 CN H A1 J7 S 200 CN H A1 J8 S 201 CN H A1 J9
S 202 CN H A1 J10 S 203 CN H A1 J11 S 204 CN H A1 J12 S 205 CN H A1
J13 S 206 CN H A1 J14 S 207 CN H A1 J15 S 208 CN H A1 J16 S 209 CN
H A1 J17 S 210 CN H A1 J18 S 211 CN H A1 J19 S 212 CN H A1 J20 S
213 CN H A1 J21 S 214 CN H A1 J22 S 215 CN H A1 J23 S 216 CN H A1
J24 S 217 CN H A1 J25 S 218 CN H A1 J26 S 219 CN H A1 J27 S 220 CN
H A1 J28 S 221 CN H A1 J29 S 222 CN H A1 J30 S 223 CN H A1 J31 S
224 CN H A1 J32 S 225 CN H A2 J1 S 226 CN H A2 J2 S 227 CN H A2 J3
S 228 CN H A2 J4 S 229 CN H A2 J5 S 230 CN H A2 J6 S 231 CN H A2 J7
S 232 CN H A2 J8 S 233 CN H A2 J9 S 234 CN H A2 J10 S 235 CN H A2
J11 S 236 CN H A2 J12 S 237 CN H A2 J13 S 238 CN H A2 J14 S 239 CN
H A2 J15 S 240 CN H A2 J16 S 241 CN H A2 J17 S 242 CN H A2 J18 S
243 CN H A2 J19 S 244 CN H A2 J20 S 245 CN H A2 J21 S 246 CN H A2
J22 S 247 CN H A2 J23 S 248 CN H A2 J24 S 249 CN H A2 J25 S 250 CN
H A2 J26 S 251 CN H A2 J27 S 252 CN H A2 J28 S 253 CN H A2 J29 S
254 CN H A2 J30 S 255 CN H A2 J31 S 256 CN H A2 J32 S 257 CN H A3
J1 S 258 CN H A3 J2 S 259 CN H A3 J3 S 260 CN H A3 J4 S 261 CN H A3
J5 S 262 CN H A3 J6 S 263 CN H A3 J7 S 264 CN H A3 J8 S 265 CN H A3
J9 S 266 CN H A3 J10 S 267 CN H A3 J11 S 268 CN H A3 J12 S 269 CN H
A3 J13 S 270 CN H A3 J14 S 271 CN H A3 J15 S 272 CN H A3 J16 S 273
CN H A3 J17 S 274 CN H A3 J18 S 275 CN H A3 J19 S 276 CN H A3 J20 S
277 CN H A3 J21 S 278 CN H A3 J22 S 279 CN H A3 J23 S 280 CN H A3
J24 S 281 CN H A3 J25 S 282 CN H A3 J26 S 283 CN H A3 J27 S 284 CN
H A3 J28 S 285 CN H A3 J29 S 286 CN H A3 J30 S 287 CN H A3 J31 S
288 CN H A3 J32 S 289 Me H A1 J1 S 290 Me H A1 J2 S 291 Me H A1 J3
S 292 Me H A1 J4 S 293 Me H A1 J5 S 294 Me H A1 J6 S 295 Me H A1 J7
S 296 Me H A1 J8 S 297 Me H A1 J9 S 298 Me H A1 J10 S 299 Me H A1
J11 S 300 Me H A1 J12 S 301 Me H A1 J13 S 302 Me H A1 J14 S 303 Me
H A1 J15 S 304 Me H A1 J16 S 305 Me H A1 J17 S 306 Me H A1 J18 S
307 Me H A1 J19 S 308 Me H A1 J20 S 309 Me H A1 J21 S 310 Me H A1
J22 S 311 Me H A1 J23 S 312 Me H A1 J24 S 313 Me H A1 J25 S 314 Me
H A1 J26 S 315 Me H A1 J27 S 316 Me H A1 J28 S 317 Me H A1 J29 S
318 Me H A1 J30 S 319 Me H A1 J31 S 320 Me H A1 J32 S 321 Me H A2
J1 S 322 Me H A2 J2 S 323 Me H A2 J3 S 324 Me H A2 J4 S 325 Me H A2
J5 S 326 Me H A2 J6 S 327 Me H A2 J7 S 328 Me H A2 J8 S 329 Me H A2
J9 S 330 Me H A2 J10 S 331 Me H A2 J11 S 332 Me H A2 J12 S 333 Me H
A2 J13 S 334 Me H A2 J14 S 335 Me H A2 J15 S 336 Me H A2 J16 S 337
Me H A2 J17 S 338 Me H A2 J18 S 339 Me H A2 J19 S 340 Me H A2 J20 S
341 Me H A2 J21 S 342 Me H A2 J22 S 343 Me H A2 J23 S 344 Me H A2
J24 S 345 Me H A2 J25 S 346 Me H A2 J26 S 347 Me H A2 J27 S 348 Me
H A2 J28 S 349 Me H A2 J29 S 350 Me H A2 J30 S 351 Me H A2 J31 S
352 Me H A2 J32 S 353 Me H A3 J1 S 354 Me H A3 J2 S 355 Me H A3 J3
S 356 Me H A3 J4 S 357 Me H A3 J5 S 358 Me H A3 J6 S 359 Me H A3 J7
S 360 Me H A3 J8 S 361 Me H A3 J9 S 362 Me H A3 J10 S 363 Me H A3
J11 S 364 Me H A3 J12 S 365 Me H A3 J13 S 366 Me H A3 J14 S 367 Me
H A3 J15 S 368 Me H A3 J16 S 369 Me H A3 J17 S 370 Me H A3 J18 S
371 Me H A3 J19 S 372 Me H A3 J20 S 373 Me H A3 J21 S 374 Me H A3
J22 S 375 Me H A3 J23 S 376 Me H A3 J24 S 377 Me H A3 J25 S 378 Me
H A3 J26 S 379 Me H A3 J27 S 380 Me H A3 J28 S 381 Me H A3 J29 S
382 Me H A3 J30 S 383 Me H A3 J31 S 384 Me H A3 J32 S 385 H Me A1
J1 S 386 H Me A1 J2 S 387 H Me A1 J3 S 388 H Me A1 J4 S 389 H Me A1
J5 S 390 H Me A1 J6 S 391 H Me A1 J7 S 392 H Me A1 J8 S 393 H Me A1
J9 S 394 H Me A1 J10 S 395 H Me A1 J11 S 396 H Me A1 J12 S 397 H Me
A1 J13 S 398 H Me A1 J14 S 399 H Me A1 J15 S 400 H Me A1 J16 S 401
H Me A1 J17 S 402 H Me A1 J18 S 403 H Me A1 J19 S 404 H Me A1 J20 S
405 H Me A1 J21 S 406 H Me A1 J22 S 407 H Me A1 J23 S 408 H Me A1
J24 S 409 H Me A1 J25 S 410 H Me A1 J26 S 411 H Me A1 J27 S 412 H
Me A1 J28 S 413 H Me A1 J29 S 414 H Me A1 J30 S 415 H Me A1 J31 S
416 H Me A1 J32 S 417 H Me A2 J1 S 418 H Me A2 J2 S 419 H Me A2 J3
S 420 H Me A2 J4 S 421 H Me A2 J5 S 422 H Me A2 J6 S 423 H Me A2 J7
S 424 H Me A2 J8 S 425 H Me A2 J9 S 426 H Me A2 J10 S 427 H Me A2
J11 S 428 H Me A2 J12 S 429 H Me A2 J13 S 430 H Me A2 J14 S 431 H
Me A2 J15 S 432 H Me A2 J16 S 433 H Me A2 J17 S 434 H Me A2 J18 S
435 H Me A2 J19 S 436 H Me A2 J20 S 437 H Me A2 J21 S 438 H Me A2
J22 S 439 H Me A2 J23 S 440 H Me A2 J24 S 441 H Me A3 J25 S 442 H
Me A2 J26 S 443 H Me A2 J27 S 444 H Me A2 J28 S 445 H Me A2 J29 S
446 H Me A2 J30 S 447 H Me A2 J31 S 448 H Me A2 J32 S 449 H Me A3
J1 S 450 H Me A3 J2 S 451 H Me A3 J3 S 452 H Me A3 J4 S 453 H Me A3
J5 S 454 H Me A3 J6 S 455 H Me A3 J7 S 456 H Me A3 J8 S 457 H Me A3
J9 S 458 H Me A3 J10 S 459 H Me A3 J11 S 460 H Me A3 J12 S 461 H Me
A3 J13 S 462 H Me A3 J14 S 463 H Me A3 J15 S 464 H Me A3 J16 S 465
H Me A3 J17 S 466 H Me A3 J18 S 467 H Me A3 J19 S 468 H Me A3 J20 S
469 H Me A3 J21 S 470 H Me A3 J22 S 471 H Me A3 J23 S 472 H Me A3
J24 S 473 H Me A3 J25 S 474 H Me A3 J26 S 475 H Me A3 J27 S 476 H
Me A3 J28 S 477 H Me A3 J29 S 478 H Me A3 J30 S 479 H Me A3 J31 S
480 H Me A3 J32 S 481 Me Me A1 J1 S 482 Me Me A1 J2 S 483 Me Me A1
J3 S 484 Me Me A1 J4 S 485 Me Me A1 J5 S 486 Me Me A1 J6 S 487 Me
Me A1 J7 S 488 Me Me A1 J8 S 489 Me Me A1 J9 S 490 Me Me A1 J10 S
491 Me Me A1 J11 S 492 Me Me A1 J12 S 493 Me Me A1 J13 S 494 Me Me
A1 J14 S 495 Me Me A1 J15 S 496 Me Me A1 J16 S 497 Me Me A1 J17 S
498 Me Me A1 J18 S 499 Me Me A1 J19 S 500 Me Me A1 J20 S 501 Me Me
A1 J21 S 502 Me Me A1 J22 S 503 Me Me A1 J23 S 504 Me Me A1 J24 S
505 Me Me A1 J25 S 506 Me Me A1 J26 S 507 Me Me A1 J27 S 508 Me Me
A1 J28 S 509 Me Me A1 J29 S 510 Me Me A1 J30 S 511 Me Me A1 J31 S
512 Me Me A1 J32 S 513 Me Me A2 J1 S 514 Me Me A2 J2 S 515 Me Me A2
J3 S 516 Me Me A2 J4 S 517 Me Me A2 J5 S 518 Me Me A2 J6 S 519 Me
Me A2 J7 S 520 Me Me A2 J8 S 521 Me Me A2 J9 S 522 Me Me A2 J10 S
523 Me Me A2 J11 S 524 Me Me A2 J12 S 525 Me Me A2 J13 S 526 Me Me
A2 J14 S 257 Me Me A2 J15 S 528 Me Me A2 J16 S 529 Me Me A2 J17 S
530 Me Me A2 J18 S 531 Me Me A2 J19 S 532 Me Me A2 J20 S 533 Me Me
A2 J21 S 534 Me Me A2 J22 S 535 Me Me A2 J23 S 536 Me Me A2 J24 S
537 Me Me A2 J25 S 538 Me Me A2 J26 S 539 Me Me A2 J27 S 540 Me Me
A2 J28 S 541 Me Me A2 J29 S 542 Me Me A2 J30 S 543 Me Me A2 J31 S
544 Me Me A2 J32 S 545 Me Me A3 J1 S 546 Me Me A3 J2 S 547 Me Me A3
J3 S 548 Me Me A3 J4 S 549 Me Me A3 J5 S 550 Me Me A3 J6 S 551 Me
Me A3 J7 S 552 Me Me A3 J8 S 553 Me Me A3 J9 S 554 Me Me A3 J10 S
555 Me Me A3 J11 S 556 Me Me A3 J12 S 557 Me Me A3 J13 S 558 Me Me
A3 J14 S 559 Me Me A3 J15 S 560 Me Me A3 J16 S 561 Me Me A3 J17 S
562 Me Me A3 J18 S 563 Me Me A3 J19 S 564 Me Me A3 J20 S 565 Me Me
A3 J21 S 566 Me Me A3 J22 S 567 Me Me A3 J23 S 568 Me Me A3 J24 S
569 Me Me A3 J25 S 570 Me Me A3 J26 S 571 Me Me A3 J27 S 572 Me Me
A3 J28 S 573 Me Me A3 J29 S 574 Me Me A3 J30 S 575 Me Me A3 J31 S
576 Me Me A3 J32 S 577 Cl Cl A1 J1 S 578 Cl Cl A1 J2 S 579 Cl Cl A1
J3 S 580 Cl Cl A1 J4 S 581 Cl Cl A1 JS S 582 Cl Cl A1 J6 S 583 Cl
Cl A1 J7 S 584 Cl Cl A1 J8 S 585 Cl Cl A1 J9 S 586 Cl Cl A1 J10 S
587 Cl Cl A1 J11 S 588 Cl Cl A1 J12 S 589 Cl Cl A1 J13 S 590 Cl Cl
A1 J14 S 591 Cl Cl A1 J15 S 592 Cl Cl A1 J16 S 593 Cl Cl A1 J17 S
594 Cl Cl A1 J18 S 595 Cl Cl A1 J19 S 596 Cl Cl A1 J20 S 597 Cl Cl
A1 J21 S 598 Cl Cl A1 J22 S 599 Cl Cl A1 J23 S 600 Cl Cl A1 J24 S
601 Cl Cl A1 J25 S 602 Cl Cl A1 J26 S 603 Cl Cl A1 J27 S 604 Cl Cl
A1 J28 S 605 Cl Cl A1 J29 S 606 Cl Cl A1 J30 S 607 Cl Cl A1 J31 S
608 Cl Cl A1 J32 S 609 Cl Cl A2 J1 S 610 Cl Cl A2 J2 S 611 Cl Cl A2
J3 S 612 Cl Cl A2 J4 S 613 Cl Cl A2 J5 S 614 Cl Cl A2 J6 S 615 Cl
Cl A2 J7 S 616 Cl Cl A2 J8 S 617 Cl Cl A2 J9 S 618 Cl Cl A2 J10 S
619 Cl Cl A2 J11 S 620 Cl Cl A2 J12 S 621 Cl Cl A2 J13 S 622 Cl Cl
A2 J14 S 623 Cl Cl A2 J15 S 624 Cl Cl A2 J16 S 625 Cl Cl A2 J17 S
626 Cl Cl A2 J18 S 627 Cl Cl A2 J19 S 628 Cl Cl A2 J20 S 629 Cl Cl
A2 J21 S 630 Cl Cl A2 J22 S 631 Cl Cl A2 J23 S 632 Cl Cl A2 J24 S
633 Cl Cl A2 J25 S 634 Cl Cl A2 J26 S 635 Cl Cl A2 J27 S 636 Cl Cl
A2 J28 S 637 Cl Cl A2 J29 S 638 Cl Cl A2 J30 S 639 Cl Cl A2 J31 S
640 Cl Cl A2 J32 S 641 Cl Cl A3 J1 S 642 Cl Cl A3 J2 S 643 Cl Cl A3
J3 S 644 Cl Cl A3 J4 S 645 Cl Cl A3 J5 S 646 Cl Cl A3 J6 S 647 Cl
Cl A3 J7 S 648 Cl Cl A3 J8 S 649 Cl Cl A3 J9 S 650 Cl Cl A3 J10 S
651 Cl Cl A3 J11 S 652 Cl Cl A3 J12 S 653 Cl Cl A3 J13 S 654 Cl Cl
A3 J14 S 655 Cl Cl A3 J15 S 656 Cl Cl A3 J16 S 657 Cl Cl A3 J17 S
658 Cl Cl A3 J18 S 659 Cl Cl A3 J19 S 660 Cl Cl A3 J20 S 661 Cl Cl
A3 J21 S 662 Cl Cl A3 J22 S 663 Cl Cl A3 J23 S 664 Cl Cl A3 J24 S
665 Cl Cl A3 J25 S 666 Cl Cl A3 J26 S 667 Cl Cl A3 J27 S 668 Cl Cl
A3 J28 S 669 Cl Cl A3 J29 S 670 Cl Cl A3 J30 S 671 Cl Cl A3 J31 S
672 Cl Cl A3 J32 S 673 H H A1 J1 -- 674 H H A1 J2 -- 675 H H A1 J3
-- 676 H H A1 J4 -- 677 H H A1 J5 -- 678 H H A1 J6 -- 679 H H A1 J7
-- 680 H H A1 J8 -- 681 H H A1 J9 -- 682 H H A1 J10 -- 683 H H A1
J11 -- 684 H H A1 J12 -- 685 H H A1 J13 -- 686 H H A1 J14 -- 687 H
H A1 J15 -- 688 H H A1 J16 -- 689 H H A1 J17 -- 690 H H A1 J18 --
691 H H A1 J19 -- 692 H H A1 J20 -- 693 H H A1 J21 -- 694 H H A1
J22 -- 695 H H A1 J23 -- 696 H H A1 J24 -- 697 H H A1 J25 -- 698 H
H A1 J26 -- 699 H H A1 J27 -- 700 H H A1 J28 -- 701 H H A1 J29 --
702 H H A1 J30 -- 703 H H A1 J31 -- 704 H H A1 J32 -- 705 H H A2 J1
-- 706 H H A2 J2 -- 707 H H A2 J3 -- 708 H H A2 J4 -- 709 H H A2 J5
-- 710 H H A2 J6 -- 711 H H A2 J7 -- 712 H H A2 J8 -- 713 H H A2 J9
-- 714 H H A2 J10 -- 715 H H A2 J11 -- 716 H H A2 J12 -- 717 H H A2
J13 -- 718 H H A2 J14 -- 719 H H A2 J15 -- 720 H H A2 J16 -- 721 H
H A2 J17 -- 722 H H A2 J18 -- 723 H H A2 J19 -- 724 H H A2 J20 --
725 H H A2 J21 -- 726 H H A2 J22 -- 727 H H A2 J23 -- 728 H H A2
J24 -- 729 H H A2 J25 -- 730 H H A2 J26 -- 731 H H A2 J27 -- 732 H
H A2 J28 -- 733 H H A2 J29 -- 734 H H A2 J30 -- 735 H H A2 J31 --
736 H H A2 J32 -- 737 H H A3 J1 --
738 H H A3 J2 -- 739 H H A3 J3 -- 740 H H A3 J4 -- 741 H H A3 J5 --
742 H H A3 J6 -- 743 H H A3 J7 -- 744 H H A3 J8 -- 745 H H A3 J9 --
746 H H A3 J10 -- 747 H H A3 J11 -- 748 H H A3 J12 -- 749 H H A3
J13 -- 750 H H A3 J14 -- 751 H H A3 J15 -- 752 H H A3 J16 -- 753 H
H A3 J17 -- 754 H H A3 J18 -- 755 H H A3 J19 -- 756 H H A3 J20 --
757 H H A3 J21 -- 758 H H A3 J22 -- 759 H H A3 J23 -- 760 H H A3
J24 -- 761 H H A3 J25 -- 762 H H A3 J26 -- 763 H H A3 J27 -- 764 H
H A3 J28 -- 765 H H A3 J29 -- 766 H H A3 J30 -- 767 H H A3 J31 --
768 H H A3 J32 -- 769 MeO H A1 J1 -- 770 MeO H A1 J2 -- 771 MeO H
A1 J3 -- 772 MeO H A1 J4 -- 773 MeO H A1 J5 -- 774 MeO H A1 J6 --
775 MeO H A1 J7 -- 776 MeO H A1 J8 -- 777 MeO H A1 J9 -- 778 MeO H
A1 J10 -- 779 MeO H A1 J11 -- 780 MeO H A1 J12 -- 781 MeO H A1 J13
-- 782 MeO H A1 J14 -- 783 MeO H A1 J15 -- 784 MeO H A1 J16 -- 785
MeO H A1 J17 -- 786 MeO H A1 J18 -- 787 MeO H A1 J19 -- 788 MeO H
A1 J20 -- 789 MeO H A1 J21 -- 790 MeO H A1 J22 -- 791 MeO H A1 J23
-- 792 MeO H A1 J24 -- 793 MeO H A1 J25 -- 794 MeO H A1 J26 -- 795
MeO H A1 J27 -- 796 MeO H A1 J28 -- 797 MeO H A1 J29 -- 798 MeO H
A1 J30 -- 799 MeO H A1 J31 -- 800 MeO H A1 J32 -- 801 MeO H A2 J1
-- 802 MeO H A2 J2 -- 803 MeO H A2 J3 -- 804 MeO H A2 J4 -- 805 MeO
H A2 J5 -- 806 MeO H A2 J6 -- 807 MeO H A2 J7 -- 808 MeO H A2 J8 --
809 MeO H A2 J9 -- 810 MeO H A2 J10 -- 811 MeO H A2 J11 -- 812 MeO
H A2 J12 -- 813 MeO H A2 J13 -- 814 MeO H A2 J14 -- 815 MeO H A2
J15 -- 816 MeO H A2 J16 -- 817 MeO H A2 J17 -- 818 MeO H A2 J18 --
819 MeO H A2 J19 -- 820 MeO H A2 J20 -- 821 MeO H A2 J21 -- 822 MeO
H A2 J22 -- 823 MeO H A2 J23 -- 824 MeO H A2 J24 -- 825 MeO H A2
J25 -- 826 MeO H A2 J26 -- 827 MeO H A2 J27 -- 828 MeO H A2 J28 --
829 MeO H A2 J29 -- 830 MeO H A2 J30 -- 931 MeO H A2 J31 -- 832 MeO
H A2 J32 -- 833 MeO H A3 J1 -- 834 MeO H A3 J2 -- 835 MeO H A3 J3
-- 836 MeO H A3 J4 -- 837 MeO H A3 J5 -- 838 MeO H A3 J6 -- 839 MeO
H A3 J7 -- 840 MeO H A3 J8 -- 841 MeO H A3 J9 -- 842 MeO H A3 J10
-- 843 MeO H A3 J11 -- 844 MeO H A3 J12 -- 845 MeO H A3 J13 -- 846
MeO H A3 J14 -- 847 MeO H A3 J15 -- 848 MeO H A3 J16 -- 849 MeO H
A3 J17 -- 850 MeO H A3 J18 -- 851 MeO H A3 J19 -- 852 MeO H A3 J20
-- 853 MeO H A3 J21 -- 854 MeO H A3 J22 -- 855 MeO H A3 J23 -- 856
MeO H A3 J24 -- 857 MeO H A3 J25 -- 858 MeO H A3 J26 -- 859 MeO H
A3 J27 -- 860 MeO H A3 J28 -- 861 MeO H A3 J29 -- 862 MeO H A3 J30
-- 863 MeO H A3 J31 -- 864 MeO H A3 J32 -- 865 CN H A1 J1 -- 866 CN
H A1 J2 -- 867 CN H A1 J3 -- 868 CN H A1 J4 -- 869 CN H A1 J5 --
870 CN H A1 J6 -- 871 CN H A1 J7 -- 872 CN H A1 J8 -- 873 CN H A1
J9 -- 874 CN H A1 J10 -- 875 CN H A1 J11 -- 876 CN H A1 J12 -- 877
CN H A1 J13 -- 878 CN H A1 J14 -- 879 CN H A1 J15 -- 880 CN H A1
J16 -- 881 CN H A1 J17 -- 882 CN H A1 J18 -- 883 CN H A1 J19 -- 884
CN H A1 J20 -- 885 CN H A1 J21 -- 886 CN H A1 J22 -- 887 CN H A1
J23 -- 888 CN H A1 J24 -- 889 CN H A1 J25 -- 890 CN H A1 J26 -- 891
CN H A1 J27 -- 892 CN H A1 J28 -- 893 CN H A1 J29 -- 894 CN H A1
J30 -- 895 CN H A1 J31 -- 896 CN H A1 J32 -- 897 CN H A2 J1 -- 898
CN H A2 J2 -- 899 CN H A2 J3 -- 900 CN H A2 J4 -- 901 CN H A2 J5 --
902 CN H A2 J6 -- 903 CN H A2 J7 -- 904 CN H A2 J8 -- 905 CN H A2
J9 -- 906 CN H A2 J10 -- 907 CN H A2 J11 -- 908 CN H A2 J12 -- 909
CN H A2 J13 -- 910 CN H A2 J14 -- 911 CN H A2 J15 -- 912 CN H A2
J16 -- 913 CN H A2 J17 -- 914 CN H A2 J18 -- 915 CN H A2 J19 -- 916
CN H A2 J20 -- 917 CN H A2 J21 -- 918 CN H A2 J22 -- 919 CN H A2
J23 -- 920 CN H A2 J24 -- 921 CN H A3 J25 -- 922 CN H A2 J26 -- 923
CN H A2 J27 -- 924 CN H A2 J28 -- 925 CN H A2 J29 -- 926 CN H A2
J30 -- 927 CN H A2 J31 -- 928 CN H A2 J32 -- 929 CN H A3 J1 -- 930
CN H A3 J2 -- 931 CN H A3 J3 -- 932 CN H A3 J4 -- 933 CN H A3 J5 --
934 CN H A3 J6 -- 935 CN H A3 J7 -- 936 CN H A3 J8 -- 937 CN H A3
J9 -- 938 CN H A3 J10 -- 939 CN H A3 J11 -- 940 CN H A3 J12 -- 941
CN H A3 J13 -- 942 CN H A3 J14 -- 943 CN H A3 J15 -- 944 CN H A3
J16 -- 945 CN H A3 J17 -- 946 CN H A3 J18 -- 947 CN H A3 J19 -- 948
CN H A3 J20 -- 949 CN H A3 J21 -- 950 CN H A3 J22 -- 951 CN H A3
J23 -- 952 CN H A3 J24 -- 953 CN H A3 J25 -- 954 CN H A3 J26 -- 955
CN H A3 J27 -- 956 CN H A3 J28 -- 957 CN H A3 J29 -- 958 CN H A3
J30 -- 959 CN H A3 J31 -- 960 CN H A3 J32 -- 961 Me Me A1 J1 -- 962
Me Me A1 J2 -- 963 Me Me A1 J3 -- 964 Me Me A1 J4 -- 965 Me Me A1
J5 -- 966 Me Me A1 J6 -- 967 Me Me A1 J7 -- 968 Me Me A1 J8 -- 969
Me Me A1 J9 -- 970 Me Me A1 J10 -- 971 Me Me A1 J11 -- 972 Me Me A1
J12 -- 973 Me Me A1 J13 -- 974 Me Me A1 J14 -- 975 Me Me A1 J15 --
976 Me Me A1 J16 -- 977 Me Me A1 J17 -- 978 Me Me A1 J18 -- 979 Me
Me A1 J19 -- 980 Me Me A1 J20 -- 981 Me Me A1 J21 -- 982 Me Me A1
J22 -- 983 Me Me A1 J23 -- 984 Me Me A1 J24 -- 985 Me Me A1 J25 --
986 Me Me A1 J26 -- 987 Me Me A1 J27 -- 988 Me Me A1 J28 -- 989 Me
Me A1 J29 -- 990 Me Me A1 J30 -- 991 Me Me A1 J31 -- 992 Me Me A1
J32 -- 993 Me Me A2 J1 -- 994 Me Me A2 J2 -- 995 Me Me A2 J3 -- 996
Me Me A2 J4 -- 997 Me Me A2 J5 -- 998 Me Me A2 J6 -- 999 Me Me A2
J7 -- 1000 Me Me A2 J8 -- 1001 Me Me A2 J9 -- 1002 Me Me A2 J10 --
1003 Me Me A2 J1l -- 1004 Me Me A2 J12 -- 1005 Me Me A2 J13 -- 1006
Me Me A2 J14 -- 1007 Me Me A2 J15 -- 1008 Me Me A2 J16 -- 1009 Me
Me A2 J17 -- 1010 Me Me A2 J18 -- 1011 Me Me A2 J19 -- 1012 Me Me
A2 J20 -- 1013 Me Me A2 J21 -- 1014 Me Me A2 J22 -- 1015 Me Me A2
J23 -- 1016 Me Me A2 J24 -- 1017 Me Me A3 J25 -- 1018 Me Me A2 J26
-- 1019 Me Me A2 J27 -- 1020 Me Me A2 J28 -- 1021 Me Me A2 J29 --
1022 Me Me A2 J30 -- 1023 Me Me A2 J31 -- 1024 Me Me A2 J32 -- 1025
Me Me A3 J1 -- 1026 Me Me A3 J2 -- 1027 Me Me A3 J3 -- 1028 Me Me
A3 J4 -- 1029 Me Me A3 J5 -- 1030 Me Me A3 J6 -- 1031 Me Me A3 J7
-- 1032 Me Me A3 J8 -- 1033 Me Me A3 J9 -- 1034 Me Me A3 J10 --
1035 Me Me A3 J11 -- 1036 Me Me A3 J12 -- 1037 Me Me A3 J13 -- 1038
Me Me A3 J14 -- 1039 Me Me A3 J15 -- 1040 Me Me A3 J16 -- 1041 Me
Me A3 J17 -- 1042 Me Me A3 J18 -- 1043 Me Me A3 J19 -- 1044 Me Me
A3 J20 -- 1045 Me Me A3 J21 -- 1046 Me Me A3 J22 -- 1047 Me Me A3
J23 -- 1048 Me Me A3 J24 -- 1049 Me Me A3 J25 -- 1050 Me Me A3 J26
-- 1051 Me Me A3 J27 -- 1052 Me Me A3 J28 -- 1053 Me Me A3 J29 --
1054 Me Me A3 J30 -- 1055 Me Me A3 J31 -- 1056 Me Me A3 J32 -- 1057
H MeO A1 J1 S 1058 H MeO A1 J2 S 1059 H MeO A1 J3 S 1060 H MeO A1
J4 S 1061 H MeO A1 J5 S 1062 H MeO A1 J6 S 1063 H MeO A1 J7 S 1064
H MeO A1 J8 S 1065 H MeO A1 J9 S 1066 H MeO A1 J10 S 1067 H MeO A1
J11 S 1068 H MeO A1 J12 S 1069 H MeO A1 J13 S 1070 H MeO A1 J14 S
1071 H MeO A1 J15 S 1072 H MeO A1 J16 S 1073 H MeO A1 J17 S 1074 H
MeO A1 J18 S 1075 H MeO A1 J19 S 1076 H MeO A1 J20 S 1077 H MeO A1
J21 S 1078 H MeO A1 J22 S 1079 H MeO A1 J23 S 1080 H MeO A1 J24 S
1081 H MeO A1 J25 S 1082 H MeO A1 J26 S 1083 H MeO A1 J27 S 1084 H
MeO A1 J28 S 1085 H MeO A1 J29 S 1086 H MeO A1 J30 S 1087 H MeO A1
J31 S 1088 H MeO A1 J32 S 1089 H MeO A2 J1 S 1090 H MeO A2 J2 S
1091 H MeO A2 J3 S 1092 H MeO A2 J4 S 1093 H MeO A2 J5 S 1094 H MeO
A2 J6 S 1095 H MeO A2 J7 S 1096 H MeO A2 J8 S 1097 H MeO A2 J9 S
1098 H MeO A2 J10 S 1099 H MeO A2 J11 S 1100 H MeO A2 J12 S 1101 H
MeO A2 J13 S 1102 H MeO A2 J14 S 1103 H MeO A2 J15 S 1104 H MeO A2
J16 S 1105 H MeO A2 J17 S 1106 H MeO A2 J18 S 1107 H MeO A2 J19 S
1108 H MeO A2 J20 S 1109 H MeO A2 J21 S 1110 H MeO A2 J22 S 1111 H
MeO A2 J23 S 1112 H MeO A2 J24 S 1113 H MeO A3 J25 S 1114 H MeO A2
J26 S 1115 H MeO A2 J27 S 1116 H MeO A2 J28 S 1117 H MeO A2 J29 S
1118 H MeO A2 J30 S 1119 H MeO A2 J31 S 1120 H MeO A2 J32 S 1121 H
MeO A3 J1 S 1122 H MeO A3 J2 S 1123 H MeO A3 J3 S 1124 H MeO A3 J4
S 1125 H MeO A3 J5 S 1126 H MeO A3 J6 S 1127 H MeO A3 J7 S 1128 H
MeO A3 J8 S 1129 H MeO A3 J9 S 1130 H MeO A3 J10 S 1131 H MeO A3
J11 S 1132 H MeO A3 J12 S 1133 H MeO A3 J13 S 1134 H MeO A3 J14 S
1135 H MeO A3 J15 S 1136 H MeO A3 J16 S 1137 H MeO A3 J17 S 1138 H
MeO A3 J18 S 1139 H MeO A3 J19 S 1140 H MeO A3 J20 S 1141 H MeO A3
J21 S 1142 H MeO A3 J22 S 1143 H MeO A3 J23 S 1144 H MeO A3 J24 S
1145 H MeO A3 J25 S 1146 H MeO A3 J26 S 1147 H MeO A3 J27 S 1148 H
MeO A3 J28 S 1149 H MeO A3 J29 S 1150 H MeO A3 J30 S 1151 H MeO A3
J31 S 1152 H MeO A3 J32 S
[0050] The benzimidazole derivative (1) of the present invention
can be produced by synthesis method (A) or synthesis method (B)
shown below in the case E is COOR.sup.3 and M is S: 8
[0051] wherein, Z represents a halogen or ammonium group, and
R.sup.1, R.sup.2, R.sup.3, A, G, J and X are as defined above.
[0052] Namely, an orthophenylenediamine compound (a2) is obtained
by reducing the nitro group of a 2-nitroaniline derivative (a1).
After reacting this with CS.sub.2 and obtaining compound (a3), it
is reacted with a halide ester derivative (a4) to obtain (a5)
followed by further reacting with a halide derivative or ammonium
salt (a6) to be able to obtain the compound (a7) of the present
invention. In addition, benzimidazole derivative (a8), in which
R.sup.3 is a hydrogen atom, can be obtained by hydrolyzing this as
necessary.
[0053] Reduction of the nitro group can be carried out, in
accordance with the conditions of an ordinary catalytic reduction,
by reacting with hydrogen gas at a temperature of room temperature
to 100.degree. C. in the presence of a catalyst such as Pd--C under
acidic, neutral or alkaline conditions. In addition, this can also
be carried out by a method in which treatment is carried out using
zinc or tin under acidic conditions, or by a method that uses zinc
powder under neutral or alkaline conditions.
[0054] The reaction between orthophenylenediamine derivative (a2)
and CS.sub.2 can be carried out according to the method described
in, for example, The Journal of Organic Chemistry (J. Org. Chem.),
1954, Vol. 19, pages 631-637 (pyridine solution) or in The Journal
of Medical Chemistry (J. Med. Chem.), 1993, Vol. 36, pages
1175-1187 (ethanol solution).
[0055] The reaction between thiobenzimidazole compound (a3) and
halide ester (a4) can be carried out by agitating at a temperature
of 0.degree. C.-200.degree. C. in the presence of a base such as
NaH, Et.sub.3N, NaOH or K.sub.2CO.sub.3 in accordance with the
conditions of an ordinary S-alkylation reaction.
[0056] The reaction between thiobenzimidazole compound (a5) and
halide derivative or ammonium salt (a6) can be carried out by
agitating at a temperature of 0.degree. C.-200.degree. C. in the
presence of a base such as NaH, Et.sub.3N, NaOH, K.sub.2CO.sub.3 or
Cs.sub.2CO.sub.3 in accordance with the conditions of an ordinary
N-alkylation or N-acylation reaction.
[0057] A hydrolysis method using an alkali such as lithium
hydroxide or an acid such as hydrochloric acid or trifluoroacetic
acid is preferably used for the elimination reaction of the carboxy
protecting group R.sup.3. 9
[0058] Namely, (b1) is obtained by protecting the amino group of
2-nitroaniline derivative (a1) with a suitable protecting group L.
This is then reacted with a halide derivative or ammonium salt (a6)
to obtain (b2), and (b3) is obtained by removing protecting group
L. An orthophenylenediamine derivative (b4) is obtained by reducing
the nitro group of (b3). After reacting this with CS.sub.2 or
KSC(.dbd.S)Oet and obtaining compound (b5), this is reacted with a
halide ester derivative (a4) to be able to obtain the benzimidazole
derivative (a7) of the present invention. In addition, this may
then be hydrolyzed as necessary to obtain a benzimidazole
derivative of the present invention in which R.sup.3 is a hydrogen
atom.
[0059] Compound (b3) can also be obtained directly by reacting an
unprotected halide derivative, ammonium salt (a6) or aldehyde
derivative (b6) with the 2-nitroaniline derivative (a1). Examples
of protecting group L include a trifluoroacetyl group, acetyl
group, t-butoxycarbonyl group and benzyl group. The reaction
between the 2-nitroaniline derivative (a1) and aldehyde derivative
(b6) can be carried out by an ordinary reduction amination under
temperature conditions of 0.degree. C.-200.degree. C. in a solvent
such as ethanol, methanol or dichloromethane using a multiple
hydrogen compound such as LiAlH.sub.4, NaBH.sub.4, NaBH.sub.3CN or
NABH(OAc).sub.3 or a reducing agent such as diborane. In addition,
the reaction between the orthophenylenediamine derivative (b4) and
CS.sub.2 can be carried out in the same manner as Synthesis Method
(A), while the reaction with KSC(.dbd.S)Oet can be carried out
according to the method described in, for example, Organic
Synthesis (OS), 1963, Vol. 4, pages 569-570. Other reactions can be
carried out in the same manner as Synthesis Method (A).
[0060] Benzimidazole derivative (1) of the present invention can be
produced according to the following Synthesis Method (C) in the
case E is COOR.sup.3, M is S and G is an amide bond: 10
[0061] wherein, Q represents a methylene group, phenylene group,
etc., Z represents a halogen, and R.sup.1, R.sup.2, R.sup.3, A, J
and X are as defined above, provided that R.sup.3 is an inactive
protecting group such as a methyl group or ethyl group under acidic
conditions.
[0062] Namely, compound (c2) is obtained by reacting
thiobenzimidazole compound (a5) with tert-butylesterhalide
derivative (c1). This is then hydrolyzed under acidic conditions to
obtain (c3). This is then condensed with amine derivative (c4) to
be able to obtain compound (c5) of the present invention. In
addition, this may be hydrolyzed as necessary to obtain the
benzimidazole derivative of the present invention in which R.sup.3
is a hydrogen atom.
[0063] A typical method using a condensation agent is used for the
conditions of condensation amidation. Examples of condensation
agents include DCC, DIPC, EDC.dbd.WSCI, WSCI--HCl, BOP and DPPA,
and these may be used alone or as a combination with HONSU, HOBt or
HOOBt. The reaction is carried out under temperature conditions of
0.degree. C.-200.degree. C. in a suitable solvent such as THF,
chloroform or t-butanol. The other reactions can be carried out in
the same manner as Synthesis Method (A).
[0064] The benzimidazole derivative (1) of the present invention
can be produced according to the following Synthesis Method (D) in
the case E is COOR.sup.3, M is S and G has an ether bond: 11
[0065] wherein, Z represents a halogen and R.sup.1, R.sup.2,
R.sup.3, A, J and X are as defined above.
[0066] Namely, compound (d2) is obtained by reacting, for example,
halide alcohol derivative (d1) with thiobenzimidazole compound
(a5). This is then reacted with phenol derivative (d3) to be able
to obtain compound (d4) of the present invention. In addition, this
may be hydrolyzed as necessary to obtain a benzimidazole derivative
in which R.sup.3 is a hydrogen atom.
[0067] The etherification reaction is carried out by Mitsunobu
reaction and similar reactions under temperature conditions of
0.degree. C.-200.degree. C. in a suitable solvent such as
N-methylmorpholine or THF using a phosphine compound such as
triphenylphosphine or tributylphosphine and an azo compound such as
DEAD or TMAD. The other reactions can be carried out in the same
manner as Synthesis Method (A).
[0068] Benzimidazole derivative (1) of the present invention can be
produced according to the following Synthesis Method (E) in the
case E is tetrazole-5-yl and M is S: 12
[0069] wherein, R.sup.1, R.sup.2, A, G, J and X are as defined
above.
[0070] The nitrile form (e1) is converted to the tetrazole form
(e2) by reacting with various azide compounds. Examples of azide
compounds include trialkyl tin azide compounds such as trimethyl
tin azide, hydrazoic acid and its ammonium salts. When using an
organic tin azide compound, roughly 1-4 moles should be used
relative to compound (e1). In addition, when using hydrazoic acid
or its ammonium salts, 1-5 moles of sodium azide and ammonium
chloride or tertiary amine such as triethylamine should be used
relative to compound (e1). Each reaction is carried out at a
temperature of 0.degree. C.-200.degree. C. by using a solvent such
as toluene, benzene or DMF.
[0071] Benzimidazole derivative (1) of the present invention can be
produced according to the following Synthesis Method (F) in the
case M is SO or SO.sub.2: 13
[0072] wherein, R.sup.1, R.sup.2, R.sup.3, A, G, J and X are as
defined above.
[0073] Namely, sulfoxide derivative (a7) and/or sulfone derivative
(f2) are obtained by reacting benzimidazole derivative (a7) with a
peroxide compound in a suitable solvent. Examples of peroxide
compounds used include perbenzoic acid, m-chloroperbenzoic acid,
peracetic acid and hydrogen peroxide, while examples of solvents
used include chloroform and dichloromethane. There are no
particular restrictions on the usage ratio of compound (a7) and a
peroxide compound, and although the ratio should be suitably
selected over a wide range, it is generally preferable to use about
1.2 to 5 moles. Each reaction is normally carried out at
0-50.degree. C., and preferably from 0.degree. C. to room
temperature, and each reaction is typically completed in about 4-20
hours.
[0074] Benzimidazole derivative (1) of the present invention can be
produced according to the following Synthesis Method (G) in the
case M is a single bond: 14
[0075] wherein, X, A, G, J and R.sup.3 are as defined above.
[0076] Namely, benzimidazole derivative (g2) of the present
invention can be obtained by reacting a known acid chloride
derivative (g1) with a diamine compound (b4). In addition,
hydrolyzing --COOR.sup.3 of (g2) as necessary allows the obtaining
of benzimidazole derivative (g3) in which R.sup.3 is a hydrogen
atom.
[0077] Furthermore, the cyclization reaction is described in the
Journal of Medical Chemistry (J. Med. Chem.), 1993, Vol. 36, pages
1175-1187.
[0078] In addition, Z-G-J described in synthesis methods (A)
through (F) can be synthesized by referring to a large number of
publications.
[0079] For example, a benzothiophene halide derivative can be
synthesized by referring to the following literature and patent
specification. 15
[0080] J. Chem. Soc. (1965), 774
[0081] J. Chem. Soc. Perkin Trans 1, (1972), 3011 16
[0082] These compounds can also be synthesized by referring to the
following literature and patent specifications. Namely, these
compounds can be synthesized not only by the reactions described in
the following literature, but also by combining typical reactions
such as oxidation-reduction or OH halogenation.
[0083] J Chem Soc, (1965), 774; Bull Chem Soc Jpn (1968), 41, 2215;
Japanese Unexamined Patent Publication No. 10-298180; Sulfur
Reports, (1999), Vol. 22, 1-47; J Chem Soc comm., (1988), 888: J.
Heterocyclic Chem., 19, 859, (1982); Synthetic Communication,
(1991), 21, 959; Tetrahedron Letters, (1992), Vol. 33, No. 49,
7499; Synthetic Communications, (1993), 23(6), 743; Japanese
Unexamined Patent Publication No. 2000-239270; J. Med. Chem.,
(1985), 28, 1896; Arch Pharm, (1975), 308, 7, 513; Khim Gerotsikl
Soedin, (1973), 8, 1026; Bull. Chem. Soc. Jpn., (1997), 70, 891; J.
Chem. Soc. Perkinl, (1973), 750; J. Chem. Soc. Chem. Comm., (1974),
849; J. Chem. Soc. Comm. (1972), 83
[0084] In particular, the hydroxymethyl form at position 3 of
benzothiophene can be synthesized easily by referring to J. Chem.
Soc. Chem. Comm., (1974), 849.
[0085] With respect to iodides, the Cl and Br forms can be obtained
by halogen exchange with NaI and so forth.
[0086] In addition, the quaternary ammonium salt derivative of
benzothiophene can be synthesized by reacting a suitable amine such
as dimethylamine with the previously mentioned benzothiophene
halide derivative. In addition, it may also be synthesized in the
following manner: 17
[0087] wherein, R represents one or more substituents in the
above-mentioned J, the number of substituents is optional, and the
substituents may be independent substituents.
[0088] Namely, cyclic benzothiophene derivative (h3) is obtained by
converting the amino group of 2-nitroaniline derivative (h1) to a
cyano form (h2) and reacting with ethyl 2-mercaptoacetate.
Moreover, carboxylic acid (h5) is obtained by cyanating the amino
group to a cyano form (h4) followed by ester hydrolysis. The
carboxylic acid is then decarboxylated to obtain (h6). Continuing,
the cyano group is reduced to convert to an amino form (h7)
followed by N-dimethylation to obtain (h8) and then followed by
N-methylation to be able to obtain quaternary salt (h9).
[0089] Cyanation of the amino group of 2-nitroaniline derivative
(h1) by converting the amino group to diazonium using, for example,
hydrochloric acid or sodium sulfite, and then further reacting with
copper (I) chloride and potassium cyanide to convert to the cyano
form.
[0090] Reaction from cyano form (h2) to benzothiophene derivative
(h3) can be carried out to obtain cyclic benzothiophene derivative
(h3) by heating with ethyl 2-mercaptoacetate in a suitable solvent
such as DMF in the presence of a suitable basic reagent by
referring to the method described in, for example, Synthetic
Communications, 23(6), 743-748 (1993); or Farmaco, Ed. Sci., 43,
1165 (1988).
[0091] With respect to the cyanation of (h3), (h3) can be converted
to the cyano form (h4) by reacting copper cyanide and t-butyl
sulfite in a suitable solvent such as DMSO under suitable
temperature conditions.
[0092] Ester hydrolysis can be carried out by routinely used
methods. For example, carboxylic acid (h5) can be obtained by ester
hydrolysis in a suitable solvent such as THF-MeOH in the presence
of a suitable basic reagent such as sodium hydroxide.
[0093] The carboxylic acid decarboxylation reaction can be carried
out by heating in a suitable solvent such as quinoline solvent in
the presence of a copper catalyst.
[0094] Reduction of the cyano group to an amino group can be
carried out to obtain the amino form by, for example, reducing in a
suitable solvent such as Et.sub.2O-THF under suitable temperature
conditions using a suitable reducing agent such as lithium aluminum
hydride.
[0095] Methylation of the amino group can be carried out by heating
in, for example, formic acid or aqueous formalin solution.
[0096] Conversion of the amino group to a quaternary salt can be
carried out by, for example, reacting with methyl iodide in ethanol
solvent.
[0097] Indole quaternary amine salt derivative can be synthesized
according to, for example, the following method: 18
[0098] wherein, R represents one or more substituents in the
above-mentioned J, the number of substituents is optional, and the
substituents may be independent substituents.
[0099] Namely, nitro form (k1) is converted to an enamine (k2) by
enanimation followed by converting to the indole form (k3) by
indole cyclization according to the method of Reissert. Moreover,
the 3.sup.rd position dimethylaminomethyl form (k5) is obtained
according to the Mannich reaction following N-dimethylation and
this is followed by N-methylation to be able to obtain the
quaternary amine salt (k6).
[0100] The enamination reaction can be carried out by, for example,
heating the O-nitrotoluene derivative (k1) with
N,N-dimethylformamide dimethylacetal and pyrrolidine in a suitable
solvent such as DMF.
[0101] The indole cyclization reaction can be carried out by
reacting at room temperature using hydrogen gas in the presence of
Raney nickel in a suitable solvent such as toluene.
[0102] N-methylation can be carried out by, for example, heating in
DMF solvent using t-butoxypotassium or dimethyl oxalate.
[0103] 3.sup.rd position dimethylaminomethylation can be carried
out by, for example, using the Mannich reaction and reacting at
room temperature in dioxane-acetic acid solvent using aqueous
formalin solution or aqueous dimethylamine solution.
[0104] In addition, the indole derivative can be synthesized by
referring to the literature of Heterocycles, Vol. 22, No. 1, 195,
(1984).
[0105] Moreover, benzothiophene, indole and other heterocyclic
halides and quaternary salts can be synthesized by referring to
other references in the literature such as Heterocyclic Compound
Chemistry, (Kondansha Scientific, H. Yamanaka, ed.).
[0106] Benzimidazole derivative of the present invention can also
be converted to a medically acceptable, non-toxic cation salt as
necessary. Examples of such salts include alkali metal ions such as
Na.sup.+ and K.sup.+, alkaline earth metal ions such as Mg.sup.2+
and Ca.sup.2+ and metal ions such as Al.sup.3+ and Zn.sup.2+, as
well as organic bases such as ammonia, triethylamine,
ethylenediamine, propanediamine, pyrrolidine, piperidine,
piperazine, pyridine, lysine, choline, ethanolamine,
N,N-dimethylethanolamine, 4-hydroxypiperidine, glucosamine and
N-methylglucamine. In particular, Na.sup.+, K.sup.+, Ca.sup.2+,
lysine, choline, N,N-dimethylethanolamine and N-methylglucamine are
preferable.
[0107] Benzimidazole derivative of the present invention strongly
inhibits human chymase activity. More specifically, IC.sub.50 is
1000 nM or less, preferably 0.01 nM or more to less than 1000 nM,
and more preferably 0.05 nM or more to less than 500 nM. The
benzimidazole derivative of the present invention having such
superior human chymase inhibitory activity can be used as a
preventive agent and/or therapeutic agent clinically applicable to
various diseases.
[0108] Benzimidazole derivative of the present invention can be
administered orally or non-orally as a pharmaceutical composition
together with a pharmaceutically allowed carrier by forming said
pharmaceutical composition into various drug forms. Examples of
non-oral administration include intravenous, subcutaneous,
intramuscular, transcutaneous, rectal, nasal and intraocular
administration.
[0109] Examples of drug forms of said pharmaceutical composition
include tablets, pills, granules, powders, liquids, suspensions,
syrups and capsules in the case of oral preparations.
[0110] Here, for the method of forming tablets, tablets can be
formed by an ordinary method using a pharmaceutically acceptable
carrier such as a vehicle, binder or disintegration agent. Pills,
granules and powders can be formed by an ordinary method using a
vehicle and so forth in the same manner as tablets. Liquids,
suspensions and syrups can be formed according to an ordinary
method using glycerin esters, alcohols, water or vegetable oil.
Capsules can be formed by filling granules, powders or liquids and
so forth into capsules made of gelatin and so forth.
[0111] Non-oral preparations can be administered in the form of an
injection preparation in the case of administration by intravenous,
subcutaneous or intramuscular administration. Examples of injection
preparations include the case in which a benzoic acid derivative is
dissolved in a water-soluble liquid agent such as physiological
saline, or the case in which it is dissolved in a non-aqueous
liquid agent composed of an organic ester such as vegetable
oil.
[0112] In the case of percutaneous administration, a drug form such
as an ointment or cream can be used. Ointments can be formed by
mixing a benzoic acid derivative with an oil or Vaseline and so
forth, while creams can be formed by mixing a benzoic acid
derivative with an emulsifier.
[0113] In the case of rectal administration, administration can be
performed in the form of a suppository using gelatin soft capsules
and so forth.
[0114] In the case of nasal administration, a preparation can be
used that is composed of a liquid or powder composition. Examples
of bases of liquid preparations that are used include water,
saline, phosphate buffer and acetate buffer, and may also contain
surfactant, antioxidant, stabilizer, preservative or thickener.
Examples of bases of powdered preparations include moisture
absorbing bases such as water-soluble polyacrylates, cellulose
lower alkyl ethers, polyethylene glycol polyvinyl pyrrolidone,
amylose and plurane, or water-insoluble bases such as celluloses,
starches, proteins, rubbers and cross-linked vinyl polymers,
although water-soluble bases are preferable. In addition, these may
also be used as a mixture. Moreover, antioxidant, colorant,
preservative, antiseptic or polysaprobic agent may be added to
powdered preparations. Said liquid preparations and powdered
preparations can be administered using a sprayer and so forth.
[0115] In the case of intraocular administration, an aqueous or
non-aqueous eye wash can be used. Aqueous eye washes can use
sterile purified water or physiological saline for the solvent. In
the case of using only sterile purified water for the solvent, it
can be used in the form of an aqueous suspended eye wash by adding
surfactant, polymer thickener and so forth. In addition, it can
also be used in the form of a soluble eye wash by adding a
solubilization agent such as non-ionic surfactant. Non-aqueous eye
washes can use a non-aqueous solvent for injection for the solvent,
and can also be used in the form of a non-aqueous suspended eye
wash.
[0116] Examples of drug forms used in the case of administration to
the eye other than as an eye wash include ophthalmic ointments,
applied liquids, sprays and inserts.
[0117] In addition, in the case of inhaling through the nose or
mouth, benzimidazole derivative of the present invention is inhaled
using, for example, an aerosol spray for inhalation by combining
with a typically used pharmaceutical vehicle in the form of a
solution or suspension. In addition, benzimidazole derivative of
the present invention can be administered in the form of a dry
powder using an inhaler in direct contact with the lungs.
[0118] Pharmaceutically allowed carriers such as isotonic agents,
preservatives, antiseptics, moisturizers, buffers, emulsifiers,
dispersants and stabilizers can be added to these various
preparations as necessary.
[0119] In addition, these various preparations can be sterilized by
performing treatment such as blending with a disinfectant,
filtering using a bacteria-trapping filter, heating or irradiating
as necessary. Alternatively, a sterile solid preparation can be
produced and used after dissolving or suspending in a suitable
sterile liquid immediately prior to use.
[0120] Although the dosage of benzimidazole derivative of the
present invention varies according to the type of disease,
administration route and symptoms, age, sex and body weight, etc.
of the patient, it is typically 1-500 mg/day/person, and preferably
10-300 mg/day/person, in the case of oral administration, and
0.1-100 mg/day/person, and preferably 0.3-30 mg/day/person, in
non-oral administration such as intravenous, subcutaneous,
intramuscular, percutaneous, rectal, nasal, intraocular or
inhalation administration.
[0121] In addition, in the case of using benzimidazole derivative
of the present invention as a preventive agent, it can be
administered in accordance with previously known methods according
to each symptom.
[0122] Examples of target diseases of the preventive agent and/or
therapeutic agent of the present invention include respiratory
diseases such as bronchial asthma, inflammatory and allergic
diseases such as allergic rhinitis, atopic dermatitis and
urticaria, cardiovascular diseases such as sclerosing vascular
lesions, vasoconstriction, peripheral circulatory disorders, renal
insufficiency and cardiac insufficiency, and bone and cartilage
metabolic diseases such as rheumatoid arthritis and
osteoarthritis.
EXAMPLES
[0123] The following provides a detailed explanation of the present
invention according to its production examples, examples and test
examples. However, the scope of the present invention is not
restricted in any sense by these examples.
Reference Example 1
[0124] Production of 5,6-dimethylbenzimidazole-2-thiol 19
[0125] 40 ml (0.66 mmol) of carbon disulfide were added to a
pyridine solution (40 ml) of 4.5 g (33 mmol) of
5,6-dimethylorthophenylenediamine. After stirring the resulting
solution for 18 hours while refluxing under heating, water was
added followed by extraction with ethyl acetate. After drying the
ethyl acetate phase with anhydrous magnesium sulfate, it was
concentrated under reduced pressure and dried for 6 hours at
80.degree. C. under reduced pressure to obtain 4.1 g of the target
compound (yield: 70%).
[0126] .sup.1H-NMR (270 MHz, DMSO-d.sup.6) (ppm): 12.30 (br, 1H),
6.91 (s, 2H), 2.21 (s, 6H)
Reference Example 2
[0127] Production of
4-(5,6-dimethylbenzimidazole-2-ylthio)butanoate ethyl Ester 20
[0128] 35 .mu.l (0.25 mmol) of triethylamine and 36 .mu.l (0.25
mmol) of 4-bromobutanoate ethyl ester were added to 36 mg (0.20
mmol) of the obtained 5,6-dimethylbenzimidazole-2-thiol. After
stirring the resulting solution for 12 hours at 80.degree. C.,
water was added followed by extraction with diethyl ether. After
drying the diethyl ether phase with anhydrous magnesium sulfate, it
was concentrated and residue was purified by silica gel column
chromatography (hexane:ethyl acetate=4:1) to obtain 54 mg of the
target compound (yield: 92%). Confirmation of the compound was
carried out by identifying it from the molecular weight using
LC-MS.
[0129] Calculated value M=292.12, Measured value
(M+H).sup.+=293.40
Reference Example 3
[0130] The following compounds were synthesized according to the
same method as Reference Example 2. Confirmation of the compounds
was carried out by identifying them from the molecular weight using
LC-MS.
[0131] 4-(benzimidazole-2-ylthio)butanoate ethyl ester
[0132] Calculated value M=264.09, Measured value
(M+H).sup.+=293.40
[0133] 4-(5,6-difluorobenzimidazole-2-ylthio)butanoate ethyl
Ester
[0134] Calculated value M=300.07, Measured value
(M+H).sup.+=301.3
Reference Example 4
[0135] Production of 3-bromomethyl-5-methylbenzo[b]thiophene 21
[0136] 5.02 g (27.7 mmol) of 5-methyl-2-nitrobenzoic acid were
dissolved in 20 ml of THF followed by dropping in 11.1 ml of 10.2 M
borane dimethylsulfide complex and heating at 80.degree. C. After
1.5 hours, 30 ml of 1 M hydrochloric acid were dropped into this
reaction system while cooling with ice and stirring. The system was
then concentrated under reduced pressure to obtain 100 ml of the
aqueous phase followed by extraction with ethyl acetate (100
ml.times.2). After washing the ethyl acetate phase with saturated
brine, the organic phase was dried with magnesium sulfate followed
by concentration under reduced pressure and drying to obtain 3.91 g
of the target compound (yield: 85%). 22
[0137] 5.5 ml (63.2 mmol) of oxalyl chloride were added to 50 ml of
dichloromethane and cooled to -60.degree. C. After 20 minutes, 9.13
ml (138.6 mmol) of DMSO were added and stirred at -60.degree. C.
followed 15 minutes later by the addition of 3.91 g (23.3 mmol) of
the 3-hydroxymethyl-p-nitrotoluene obtained in Step 1 at
-60.degree. C. and stirring. After 30 minutes, 45 ml of
triethylamine were dropped in at -60.degree. C. and then returned
to room temperature. After concentrating under reduced pressure,
0.1 M hydrochloric acid was added to the residue followed by
extraction with ethyl acetate (150 ml.times.2). The organic phase
was then dried with magnesium sulfate and concentrated under
reduced pressure to obtain 5.02 g of the target compound (crude
yield: 130%). 23
[0138] 5.02 g (63.2 mmol) of the 3-formyl-p-nitrotoluene obtained
in Step 2 were dissolved in 50 ml of DMF followed by the addition
of 3.06 ml (28.1 mmol) of ethyl mercaptoacetate and 4.85 g (35.1
mmol) of potassium carbonate and stirring at 50.degree. C. After
9.5 hours, the temperature was raised to 80.degree. C. followed by
additional heating for 100 minutes. Following completion of the
reaction, 250 ml of water were added to the reaction solution
followed by extraction with ethyl acetate (100 ml.times.3) and
drying with magnesium sulfate. After concentrating the solvent
under reduced pressure, the residue was purified by silica gel
column chromatography (hexane:ethyl acetate=8:1) followed by
additionally purifying by silica gel column chromatography
(hexane:ethyl acetate=10:1) to obtain 2.48 g (11.2 mmol) of the
target compound (yield: 48%).
[0139] .sup.1H-NMR (400 MHz, CDCl.sub.3) (ppm): 7.98 (s, 1H), 7.73
(d, 1H, J=8.28 Hz), 7.65 (s, 1H), 7.27 (d, 1H, J=8.32 Hz), 4.39 (q,
2H), 2.47 (s, 3H), 1.41 (s, 3H) 24
[0140] 30 ml of a solution of methanol, THF and 2 M aqueous sodium
hydroxide solution (1:1:1) were added to 2.17 g (9.87 mmol) of the
2-carboxyethyl-5-methylbenzo[b]thiophene obtained in Step 3 and
refluxed. After 20 minutes, the solution was neutralized with acid
followed by concentration under reduced pressure and recovery of
the precipitate. This was then washed with 50 ml of water and dried
to obtain 2.03 g (10.5 mmol) of the target compound (crude yield:
107%).
[0141] .sup.1H-NMR (400 MHz, CDCl.sub.3) (ppm): 7.94 (s, 1H), 7.74
(d, 1H, J=8.56 Hz), 7.69 (s, 1H), 7.27 (d, 1H, J=8.30 Hz), 2.47 (s,
3H) 25
[0142] 2.03 g (9.87 mmol) of the
2-carboxy-5-methylbenzo[b]thiophene obtained in Step 4 were
dissolved in 10 ml of quinoline followed by the addition of 799.2
mg of copper powder and heating to 190.degree. C. After 100
minutes, the solution was cooled followed by the addition of 40 ml
of 0.5 M hydrochloric acid and extraction with ethyl acetate (40
ml.times.2). The organic phase was washed with 40 ml of water and
then dried with magnesium sulfate. After concentrating the solvent
under reduced pressure, it was purified by silica gel column
chromatography (hexane:ethyl acetate=20:1) to obtain 1.41 g (9.51
mmol) of the target compound (yield of the two steps from Step 4:
96%).
[0143] .sup.1H-NMR (270 MHz, CDCl.sub.3) (ppm): 7.76 (d, 1H, J=8.24
Hz), 7.62 (s, 1H), 7.40 (d, 1H, J=5.44 Hz), 7.24 (m, 1H), 7.17 (d,
1H, J=8.24 Hz), 2.47 (s, 3H) 26
[0144] 10 ml of dichloromethane were added to 1.33 g (9.97 mmol) of
aluminum trichloride followed by cooling to -65.degree. C. with dry
ice and acetone. After 10 minutes, 1.12 ml (10.0 mmol) of
trichloroacetylchloride were dropped in. After an additional 20
minutes, 10 ml of dichloromethane solution containing 1.41 g (9.51
mmol) of the 5-methylbenzo[b]thiophene obtained in Step 5 were
dropped in and then stirred at about -65.degree. C. After 1 hour
and 40 minutes, the temperature was raised to -40.degree. C. After
an additional 1 hour and 10 minutes, the temperature was raised to
0.degree. C. After another 1 hour and 40 minutes, 10 ml of 1 M
hydrochloric acid were added and stirred. After adding 20 ml of
water to the reaction system, removing the dichloromethane phase by
a liquid separation procedure and then additionally extracting the
aqueous phase with ethyl acetate, the aqueous phase was combined
with the dichloromethane phase and then concentrated under reduced
pressure. 3.2 g of the resulting residue were purified by silica
gel column chromatography (silica gel: 120 g, hexane) to obtain
686.7 mg (2.34 mmol) of the target compound (yield: 24%).
[0145] .sup.1H-NMR (400 MHz, CDCl.sub.3) (ppm): 8.89 (s, 1H), 8.51
(s, 1H), 7.78 (d, 1H, J=8.28 Hz), 7.30 (d, 1H, J=8.32 Hz), 2.53 (s,
3H) 27
[0146] 686.7 mg (2.34 mmol) of the
3-chloromethylcarbonyl-5-methylbenzo[b]- thiophene obtained in Step
6 were dissolved in 2.0 ml of THF and 3.0 ml of MeOH followed by
the addition of 2 ml of 2 M aqueous sodium hydroxide solution and
stirring at room temperature. After 2 hours and 45 minutes, 5 ml of
2 M aqueous sodium hydroxide solution were added followed by
heating to 60.degree. C. After cooling 30 minutes later and adding
10 ml of 2 M hydrochloric acid and 30 ml of water, the solution was
extracted with ethyl acetate followed by concentration under
reduced pressure and drying to obtain 438.9 mg (2.28 mmol) of the
target compound (yield: 97%).
[0147] .sup.1H-NMR (400 MHz, CDCl.sub.3) (ppm): 8.44 (s, 1H), 8.36
(s, 1H), 7.74 (d, 1H, J=8.04 Hz), 7.22 (d, 1H, J=8.28 Hz), 2.50 (s,
3H) 28
[0148] 438.9 mg (2.28 mmol) of the
3-carboxy-5-methylbenzo[b]thiophene obtained in Step 7 were
dissolved in 5 ml of THF followed by the addition of BH.sub.3.THF
complex solution and stirring at room temperature. After 1 hour and
15 minutes, 4 ml of 2 M hydrochloric acid were added and stirred
followed by the addition of 50 ml of ethyl acetate. The organic
phase was washed with 30 ml of water and dried with magnesium
sulfate followed by concentration under reduced pressure. The
resulting residue was purified with Biotage (hexane:ethyl
acetate=4:1) to obtain 347.6 mg (1.95 mmol) of the target compound
(yield: 86%).
[0149] .sup.1H-NMR (400 MHz, CDCl.sub.3) (ppm): 7.74 (d, 1H, J=8.04
Hz), 7.65 (s, 1H), 7.34 (s, 1H), 7.19 (d, 1H, J=8.28 Hz), 4.89 (s,
2H), 2.48 (s, 3H) 29
[0150] 326 mg (1.83 mmol) of the
3-hydroxymethyl-5-methylbenzo[b]thiophene obtained in Step 8 were
dissolved in 10 ml of dichloromethane followed by the addition of
0.262 ml of phosphorous tribromide and stirring at room
temperature. After 30 minutes, 30 ml of water were added followed
by stirring for 10 minutes and extracting with dichloromethane (30
ml.times.2). The organic phase was then concentrated under reduced
pressure and dried to obtain 397.5 mg (1.65 mmol) of the target
compound (yield: 90%).
[0151] .sup.1H-NMR (270 MHz, CDCl.sub.3) (ppm): 7.74-7.67 (m, 2H),
7.46 (s, 1H), 7.22 (d, 1H, J=8.24 Hz), 4.74 (s, 2H), 2.51 (s,
3H)
Reference Example 5
[0152] Production of
((4-methylbenzo[b]thiophene-3-yl)methyl)trimethylammo- nium iodide
30
[0153] 76.07 g (500 mmol) of 2-amino-3-nitrotoluene were added to
100 g (990 mmol) of 36% hydrochloric acid and 500 g of ice followed
by stirring vigorously at 0.degree. C. 80 ml of an aqueous solution
containing 37.95 g (550 mmol) of sodium nitrite was then slowly
dropped in while holding the temperature to 0-5.degree. C.
Following completion of dropping, 100 ml of toluene were added
followed by stirring for 30 minutes at 0.degree. C. The reaction
solution was placed in an ice-NaCl bath followed by slowly adding
sodium bicarbonate while stirring vigorously to neutralize the pH
to about 6 (diazonium salt solution (1)).
[0154] An aqueous solution (550 ml) containing 260.5 g (4000 mmol)
of potassium cyanide was slowly added at 0.degree. C. to an aqueous
solution (650 ml) containing 99.0 g (1000 mmol) of copper (I)
chloride followed by stirring for 90 minutes and then adding 200 ml
of ethyl acetate. The diazonium salt solution (1) prepared above
was then dropped into this solution over the course of 30 minutes
while holding the temperature to 0-5.degree. C. The solution was
then stirred for 12 hours in an ice bath and then warmed to room
temperature. After extracting the reaction solution with ethyl
acetate and washing the organic phase with water, it was dried with
magnesium sulfate followed by concentrating the solvent under
reduced pressure. The residue was then purified by silica gel
column chromatography (hexane:ethyl
acetate=20:1.fwdarw.10:1.fwdarw.7:1.f- wdarw.5:1.fwdarw.3:1) to
obtain 58.63 g (362 mmol) of the target compound (yield: 72%).
[0155] .sup.1H-NMR (270 MHz, CDCl.sub.3) (ppm): 7.68 (2H, m), 8.13
(1H, m), 2.715 (3H, s) 31
[0156] A DMF solution (250 ml) containing 58.63 g (362 mmol) of the
2-cyano-3-nitrotoluene obtained in Step 1, 47.5 g (395 mmol) of
ethyl 2-mercaptoacetate and 57.5 g (416 mmol) of potassium
carbonate was stirred for 12 hours at 100.degree. C. The reaction
solution was then concentrated, as is, under reduced pressure to
remove the DMF to a certain degree. Water was added to dissolve
inorganic substances followed by extraction with ethyl acetate.
After washing the organic phase with water, it was dried with
magnesium sulfate followed by concentration of the solvent under
reduced pressure. The residue was then purified by silica gel
column chromatography (hexane:ethyl acetate=10:1) to obtain 62.86 g
(267 mmol) of the target compound (yield: 74%).
[0157] .sup.1H-NMR (270 MHz, CDCl.sub.3) (ppm): 7.54 (d, 1H,), 7.29
(t, 1H), 7.03 (d, 1H), 6.28 (s, 2H), 4.35 (q, 2H), 2.82 (s, 3H),
1.39 (t, 3H) 32
[0158] After replacing the reaction system with nitrogen, 82.0 g
(795 mmol) of t-butyl nitrite and 30.9 g (345 mmol) of copper
cyanide were added to 250 ml of DMSO and dissolved by stirring for
30 minutes at 55.degree. C. Moreover, a DMSO solution (100 ml)
containing 62.2 g (265 mmol) of the
3-amino-2-ethoxycarbonyl-4-methylbenzo[b]thiophene obtained in Step
2 was slowly dropped in over the course of 2 hours while holding
the temperature at 55.degree. C. After warming the reaction
solution to 60.degree. C. and stirring for 140 minutes, it was
cooled to 0.degree. C. followed by slowly adding water and stirring
for 1 hour at 0.degree. C. The reaction solution was then filtered
with Celite to remove impurities, and after extracting with
dichloromethane and washing the organic phase with water, it was
dried with magnesium sulfate followed by concentrating the solvent
under reduced pressure. The residue was then purified by silica gel
column chromatography (hexane:ethyl acetate=20:1.fwdarw.15:1.f-
wdarw.10:1) to obtain 15.59 g (63.6 mmol) of the target compound
(yield: 24%).
[0159] .sup.1H-NMR (270 MHz, CDCl.sub.3) (ppm): 7.73 (d, 1H), 7.44
(t, 1H), 7.30 (d, 1H), 4.50 (q, 2H), 2.95 (s, 3H), 1.47 (t, 3H)
33
[0160] 15.59 g (63.6 mmol) of the
3-cyano-2-ethoxycarbonyl-4-methylbenzo[b- ]thiophene obtained in
Step 3 were dissolved in a mixture of methanol (150 ml), THF (150
ml) and water (150 ml) followed by the addition of 30 ml of 5 M
aqueous sodium hydroxide solution and stirring for 2 hours at room
temperature. After concentrating the solvent under reduced
pressure, the pH was lowered to 4 by addition of 1 M hydrochloric
acid and, after extracting with ethyl acetate and washing the
organic phase with water, it was dried with magnesium sulfate. The
solvent was then concentrated under reduced pressure to obtain
3-cyano-2-carboxy-4-methylbenzo[b]thioph- ene. This and 1.27 g (20
mmol) of copper powder were added to 18 ml of quinoline followed by
stirring for 2 hours at 150.degree. C. After cooling the reaction
solution, it was filtered with Celite and the pH of the filtrate
was lowered to 3 by addition of hydrochloric acid to transfer the
quinoline as the solvent to the aqueous phase followed by
extraction with ethyl acetate. After washing the organic phase with
water, it was dried with magnesium sulfate and the solvent was
concentrated under reduced pressure. The residue was then purified
by silica gel column chromatography (hexane:ethyl acetate=20:1) to
obtain 9.10 g (52.6 mmol) of the target compound (yield of the two
steps: 83%).
[0161] .sup.1H-NMR (270 MHz, CDCl.sub.3) (ppm): 8.15 (s, 1H), 7.74
(d, 1H), 7.36 (t, 1H), 7.25 (d, 1H), 2.91 (s, 3H) 34
[0162] After dropping a diethyl ether (20 ml) and THF (20 ml)
solution containing 9.10 g (52.6 mmol) of the
3-cyano-4-methylbenzo[b]thiophene obtained in Step 4 into 50 ml of
a diethyl ether suspension of 2.0 g (53 mmol) of lithium aluminum
hydride over the course of 15 minutes at 0.degree. C., the solution
was stirred for 30 minutes at room temperature. Following
completion of the reaction, excess LAH in the reaction solution was
treated with hydrochloric acid followed by the addition of aqueous
sodium hydroxide solution to make alkaline. After saturating the
aqueous phase with potassium carbonate, extracting with
dichloromethane and washing the organic phase with water, it was
dried with magnesium sulfate. The solvent was then concentrated
under reduced pressure to obtain
3-aminomethyl-4-methylbenzo[b]thiophene. 11.5 (250 mmol) of formic
acid and 10.0 g (123 mmol) of 37% aqueous formaldehyde solution
were sequentially added to this followed by stirring for 5 hours at
80.degree. C. Following completion of the reaction, after adding
aqueous hydrochloric acid solution to the reaction solution, it was
concentrated under reduced pressure to remove the formic acid and
formaldehyde. Aqueous sodium hydroxide solution was then added to
make the solution alkaline followed by extraction with
dichloromethane. After washing the organic phase with water, it was
dried with magnesium sulfate and the solvent was concentrated under
reduced pressure. The residue was then purified by silica gel
column chromatography (hexane:ethyl acetate 10:1) to obtain 2.61 g
(12.8 mmol) of the target compound (yield of the two steps: 24%).
Confirmation of the compound was carried out by identifying from
.sup.1H-NMR.
[0163] .sup.1H-NMR (270 MHz, CDCl.sub.3) (ppm): 7.66 (s, 1H),
7.26-7.09 (m, 3H), 3.65 (s, 2H), 2.85 (s, 3H), 2.27 (s, 6H) 35
[0164] 3.69 g (26 mmol) of methyl iodide were added to 20 ml of an
ethanol solution containing 2.61 g (12.8 mmol) of the
3-((N,N-dimethylamino)methy- l)-4-methylbenzo[b]thiophene obtained
in Step 5 followed by stirring for 18 hours at room temperature. As
this results in a white suspension, after filtering out the excess
methyl iodide and solvent, it was washed with ethanol (10
ml.times.2) and diethyl ether (10 ml.times.3) to obtain 3.08 g
(8.88 mmol) of the target compound in the form of a white solid
(yield: 69%).
[0165] .sup.1H-NMR (270 MHz, DMSO)(ppm): 8.19 (s, 1H), 7.93 (d,
1H), 7.36-7.25 (m, 2H), 4.91 (s, 2H), 3.05 (s, 9H), 2.77 (s,
3H)
Reference Example 6
Production ((1,4-dimethylindole-3-yl)methyl)methylammonium
Iodide
[0166] 36
[0167] 30.5 g (256 mmol) of N,N-dimethylformamidedimethylacetal and
10.9 g (153 mmol) of pyrrolidine were added to 150 ml of an
N,N-dimethylformamide solution containing 19.4 g (128 mmol) of
2,3-dimethylnitrobenzene. After stirring the resulting solution for
72 hours at 120.degree. C., it was concentrated as is. 100 ml of
toluene were added to the resulting brown oily substance followed
by the addition of 11 g of Raney nickel (50%, aqueous slurry,
pH>9) and stirring. The inside of the reaction vessel was
replaced with hydrogen gas followed by stirring for 20 hours at
room temperature in a hydrogen gas atmosphere. After filtering the
reaction solution with Celite, the filtrate was concentrated to
obtain 30 g of a black solution. This was then purified by silica
gel column chromatography (hexane:ethyl acetate=10:1) to obtain
11.33 g (86 mmol) of the target compound (yield of the two steps:
67%). Confirmation of the compound was carried out by identifying
using .sup.1H-NMR.
[0168] .sup.1H-NMR (270 MHz, CDCl.sub.3) (ppm): 7.28-7.07 (m, 3H),
6.93 (m, 1H), 6.57 (m, 1H), 2.57 (s, 3H) 37
[0169] 12.7 g (134 mmol) of t-butoxypotassium and 80 ml of
N,N-dimethylformamide were added to a pre-dried reaction vessel.
8.9 g (67.9 mmol) of the 4-methylindole obtained in Step 1 were
added followed by stirring for 35 minutes at room temperature. 15.8
g (134 mmol) of dimethyl oxalate were added to this followed by
stirring for 5 hours and 30 minutes at 120.degree. C. After
concentrating under reduced pressure, 200 ml of water were added
followed by treatment with 1 M hydrochloric acid to make acidic (pH
3) followed by extraction with ethyl acetate (200 ml.times.2) and
drying with anhydrous magnesium sulfate. After distilling off the
solvent under reduced pressure, it was purified by silica gel
column chromatography (hexane:ethyl acetate=5:1) to obtain 9.24 g
(53 mmol) of the target compound (yield: 94%). Confirmation of the
compound was carried out by identifying using .sup.1H-NMR.
[0170] .sup.1H-NMR (270 MHz, CDCl.sub.3) (ppm): 7.25-7.09 (m, 2H),
7.03 (m, 1H), 6.90 (m, 1H), 6.49 (m, 1H), 3.78 (s, 3H), 2.55 (s,
3H) 38
[0171] 5.9 ml (72.0 mmol) of 37% aqueous formaldehyde solution and
7.08 ml (78 mmol) of 50% aqueous dimethylamine solution were
sequentially added to a mixed system containing 25 ml each of
1,4-dioxane and acetic acid. After cooling to room temperature, as
this reaction generates heat, 10 ml of a 1,4-dioxane solution
containing 9.24 g (63.6 mmol) of the 1,4-dimethylindole obtained in
Step 2 were added followed by stirring for 2 hours at room
temperature. The reaction solution was then concentrated as is. 5 M
aqueous sodium hydroxide solution were then added to the residue to
make alkaline (pH=12) and bring to a total volume of 100 ml
followed by extraction with ethyl acetate (100 ml.times.2). The
organic phase was then dried with anhydrous magnesium sulfate and
concentrated under reduced pressure to obtain 12.93 g (63.9 mmol)
of the target compound (crude yield: 100.4%). Confirmation of the
compound was carried out by identifying using .sup.1H-NMR.
[0172] .sup.1H-NMR (270 MHz, CDCl.sub.3) (ppm): 7.15-7.06 (m, 2H),
6.91 (m, 1H), 6.85 (m, 1H), 3.71 (s, 3H), 3.59 (s, 2H), 2.74 (s,
3H), 2.27 (s, 6H) 39
[0173] 12.93 g (63.6 mmol) of the
1,4-dimethyl-3-(N,N-dimethylaminomethyl)- indole obtained in Step 3
were dissolved in 60 ml of ethanol followed by the addition of 4.36
ml (70 mmol) of methyl iodide. A white precipitate formed after
stirring for 2 hours at room temperature. This was then filtered,
washed twice with 10 ml of ethanol and dried in a vacuum to obtain
16.66 g (48.4 mmol) of the target compound (yield of the two steps:
76%). Confirmation of the compound was carried out by identifying
using .sup.1H-NMR.
[0174] .sup.1H-NMR (270 MHz, DMSO) (ppm): 7.65 (s, 1H), 7.36 (d,
1H), 7.13 (t, 1H), 6.91 (d, 1H), 4.74 (s, 2H), 3.82 (s, 3H), 3.01
(s, 9H), 2.65 (s, 3H)
Reference Example 7
[0175] 40
[0176] 6.48 g (33.2 mmol) of 4-bromobutanoate ethyl ester were
added to 10 ml of an ethanol solution containing 5.0 g (27.7 mmol)
of 5-methoxybenzimidazole-2-thiol followed by stirring for 1 hour
at 80.degree. C. and adding 90 ml of ethyl acetate. The reaction
solution was returned to room temperature and the formed crystals
were filtered out followed by drying to obtain 9.34 g of the target
compound (yield: 90%).
[0177] .sup.1H-NMR (270 MHz, CDCl.sub.3) (ppm): 7.65 (d, 1H, J=8.91
Hz), 7.24 (s, 1H), 7.00 (dd, 1H, J=2.43, 8.91 Hz), 4.21 (q, 2H,
J=7.29 Hz), 3.83 (s, 3H), 3.74 (m, 2H), 2.61 (m, 2H), 2.10 (m, 2H),
1.30 (t, 3H, J=7.29 Hz)
Example 1
[0178] 41
[0179] 480 mg (2.49 mmol) and 10 ml of tetrahydrofuran were added
to a pre-dried reaction vessel. 505 mg (1.91 mmol) of the
4-(benzimidazole-2ylthio)butanoate ethyl ester obtained in
Reference Example 3 and 724 mg (2.10 mmol) of
((1,4-dimethylindole-3-yl)methyl)trim- ethylammonium iodide were
added followed by stirring for 6 hours at 80.degree. C. After
filtering the solution by passing through Celite, it was
concentrated under reduced pressure. The residue was then purified
by silica gel column chromatography (dichloromethane:ethyl
acetate=8:1) to obtain 540 mg (1.28 mmol) of
4-(1-((1,4-dimethylindole-3-yl)methyl)benzim-
idazole-2-ylthio)butanoate ethyl ester (yield: 67%).
[0180] 2.0 ml of a 2M aqueous sodium hydroxide solution were then
added to 6 ml of a methanol solution containing 540 mg (1.28 mmol)
of the resulting 4-(1-((1,4-dimethylindole-3-yl)methyl)
benzimidazole-2-ylthio)b- utanoate ethyl ester. After stirring for
16 hours at room temperature, 6 M hydrochloric acid was added to
stop the reaction. The solvent was removed to a certain degree by
concentration under reduced pressure followed by extraction with
ethyl acetate. After washing the ethyl acetate phase with saturated
brine, it was dried with anhydrous magnesium sulfate. After
distilling off the solvent under reduced pressure, it was purified
by silica gel column chromatography (dichloromethane:methanol=8:1)
to obtain 502 mg (1.28 mmol) of the target compound (yield: 100%).
Confirmation of the compound was carried out by identifying from
its molecular weight using LC-MS.
[0181] Calculated value M=393.15, Measured value
(M+H).sup.+=394.2
Example 2
[0182] The following compounds and the compounds in the following
table were synthesized according to the same method as Example 1
using the compounds indicated in Reference Example 2 or 3 as well
as various quaternary ammonium salts or halide derivatives
synthesized with reference to Reference Examples 4-6 and other
references described in the text. Confirmation of the compounds was
carried out by identifying from their molecular weights using
LC-MS. However, some of the compounds were synthesized using
conditions that somewhat differed from those of Example 1,
including conditions such as the use of DMF and so forth for the
solvent and the use of potassium carbonate for the base in
coupling, the use of THF and EtOH for the solvent in hydrolysis,
and the use of a temperature of room temperature to 50.degree.
C.
[0183] In addition, the following compounds were similarly
synthesized.
[0184]
4-(1-(2-(1-methylindole-3-yl)ethyl)benzimidazole-2-ylthio)butanoic
acid (Compound No. 1153)
[0185] In this case however, a methanesulfonate ester of
2-(1-methylindole-3-yl)ethanol was used instead of quaternary
ammonium salt and halide derivative. Identification of the compound
was carried out using LC-MS. The yield was 19% (two steps of
N-alkylation and ester hydrolysis).
[0186] Calculated value M=393.15, Measured value
(M+H).sup.+=394.0
[0187]
4-(1-(4-methyl-7-chlorobenzo[b]thiophene-3-yl)methyl)benzimidazole--
2-ylthio)butanoic Acid (Compound No. 1154)
[0188] Yield: 15% (two steps of N-alkylation and ester
hydrolysis)
[0189] Calculated valve M=430.06, Measured value
(M+H).sup.+=431.2
[0190] .sup.1H-NMR (270 MHz, DMSO-d.sub.6) (ppm): 12.17 (br, 1H),
7.63 (d, 1H, J=7.83 Hz), 7.47-7.40 (m, 2H), 7.26 (d, 1H, J=8.10
Hz), 7.22-7.11 (m, 2H), 6.46 (s, 1H), 5.86 (s, 2H), 3.34 (t, 2H,
J=7.29 Hz), 2.84 (s, 3H), 2.34 (t, 2H, J=7.29 Hz), 1.94 (m, 2H)
[0191] 4-(1-(4-methyl-7-bromobenzo[b]thiphene-3-yl)methyl)
benzoimidazole-2-ylthio)butanoic Acid (Compound No. 1155)
[0192] Yield: 56% (two steps of N-alkylation and ester
hydrolysis)
[0193] Calculated value M=474.01, Measured value
(M+H).sup.+=477.0
[0194] .sup.1H-NMR (270 MHz, DMSO-d.sub.6) (ppm): 12.18 (br, 1H),
7.63 (d, 1H, J=7.56 Hz), 7.53 (d, 1H, J=7.56 Hz), 7.46 (d, 1H,
J=7.56 Hz), 7.22-7.11 (m, 3H), 6.46 (s, 1H), 5.85 (s, 2H), 3.34 (t,
2H, J=7.29 Hz), 2.83 (s, 3H), 2.34 (t, 2H, J=7.29 Hz), 1.97 (m,
2H)
2 Measured value Yield (two steps) Compound No. Calculated value M
(M + H).sup.+ % 35 393.15 394.2 10 36 393.15 394.2 15 37 393.15
394.1 25 38 393.15 394.1 19 39 393.15 394.2 67 40 407.17 408.2 3 41
413.10 414.3 74 42 397.13 398.3 26 43 409.15 410.1 3 44 455.17
456.2 1 45 517.18 518.1 8 46 413.10 414.1 53 47 397.13 398.1 56 48
409.15 410.3 81 49 404.13 405.2 31 50 409.15 410.1 24 52 382.08
383.2 65 54 416.04 417.3 100 56 396.10 397.3 63 58 396.10 397.1 95
59 416.04 417.1 44 63 410.11 411.3 33 514 408.17 408.3 83 519
421.18 422.2 36 521 441.13 442.3 58 532 410.11 411.3 65 534 444.07
445.3 80 536 424.13 425.3 73 538 424.13 425.2 11 615 461.07 462.0
89 628 450.00 451.0 78
Example 3
[0195] Production of Compound No. 148 42
[0196] 740 mg (2.8 mmol) of 4-methoxy-2nitrotrifluoroanilide were
dissolved in 5 ml of dimethylformamide followed by the sequential
addition of 503 mg (3.64 mmol) of potassium carbonate and 773 mg
(3.4 mmol) of 3-bromomethylbenzothiophene and heating to
100.degree. C. After 12 hours, 5 ml of 5 M aqueous sodium hydroxide
solution were added and refluxed, as is, for 1 hour. After 15
minutes, the solution was cooled to room temperature followed by
the addition of 10 ml of water and extraction with chloroform.
After washing the organic phase twice with 25 ml of saturated brine
and drying with magnesium sulfate, it was concentrated and dried
under reduced pressure. The residue was then purified by silica gel
column chromatography (hexane:ethyl acetate=60:1) to obtain 400 mg
of ((benzothiophene-3-yl)methyl)(4-methoxy-2-nitrophenyl- )amine in
the form of an orange powder (yield: 44%). 43
[0197] 4 ml of ethanol and 4 ml of 1,4-dioxane were added to 400 mg
(1.23 mmol) of
((benzothiophene-3-yl)methyl)(4-methoxy-2-nitrophenyl)amine
followed by the addition of 0.34 ml of 5 M aqueous sodium hydroxide
solution and refluxing while heating. After 15 minutes, the
reaction solution was removed from the oil bath followed by the
divided addition of 320 mg (4.9 mmol) of zinc powder. The reaction
solution was again refluxed while heating for 1 hour. After
allowing to cool to room temperature, the zinc was filtered out and
the filtrate was concentrated under reduced pressure followed by
extraction with chloroform. The organic phase was washed twice with
5 ml of saturated brine followed by drying with magnesium sulfate,
concentration under reduced pressure and drying to obtain 309 mg of
a brown oil.
[0198] Continuing, the resulting brown oil was dissolved in 10 ml
of ethanol followed by the addition of 2.5 ml (42 mmol) of carbon
disulfide and refluxing. After 12 hours, the reaction solution was
returned to room temperature and concentrated under reduced
pressure followed by the addition of 2 ml of ethanol and
irradiating with ultrasonic waves to break into fine fragments that
were then filtered. The resulting powder was washed twice with 2 ml
of ethanol and then dried to obtain 120 mg (0.37 mmol) of
1-((benzothiophene-3-yl)methyl)-5-methoxybenzimidazole-2-t- hiol
(yield of the two steps: 30%). 44
[0199] 101 mg (0.30 mmol) of
1-((benzothiophene-3-yl)methyl)-5-methoxybenz- imidazole-2-thiol
were dissolved in 2 ml of dimethylformamide followed by the
addition of 62 mg (0.45 mmol) of potassium carbonate and 53 mg
(0.40 mmol) of 4-bromobutanoate ethyl ester and heating to
80.degree. C. After 12 hours, the reaction solution was
concentrated under reduced pressure and extracted with diethyl
ether followed by washing twice with 10 ml of saturated brine and
drying with magnesium sulfate. The solvent was then concentrated
under reduced pressure and the residue was purified by silica gel
column chromatography (hexane:ethyl acetate=1:1) to obtain 60 mg
(0.136 mmol) of
4-(1-((benzothiophene-3-yl)methyl)-5-methoxybenzimidaz-
ole-2-ylthio)butanoate ethyl ester (yield: 45%). 45
[0200] 60 mg (0.136 mmol) of
4-(1-((benzothiophene-3-yl)methyl)-5-methoxyb-
enzimidazole-2-ylthio)butanoate ethyl ester were dissolved in 2 ml
of methanol followed by the addition of 0.5 ml of 4 M aqueous
sodium hydroxide solution. After stirring for 3 hours at 50.degree.
C., 6 M hydrochloric acid was added to stop the reaction followed
by concentrating under reduced pressure and extracting with
chloroform. After washing the organic phase with saturated brine,
it was dried with anhydrous magnesium sulfate. The solvent was
concentrated under reduced pressure and the residue was purified by
silica gel column chromatography (ethyl acetate) to obtain 20 mg
(0.048 mmol) of the target compound (yield: 36%). Confirmation of
the compound was carried out by identifying from the molecular
weight using LC-MS.
[0201] Calculated value M=412.09, Measured value
(M+H).sup.+=413.1
Example 4
[0202] Production of Compound No. 135
[0203] The target compound was obtained according to the same
method as Example 3.
[0204] However, ((1,4-dimethylindole-3-yl)methyl) trimethylammonium
iodide was used in the reaction corresponding to Step 1.
[0205] Confirmation of the compound was carried out by identifying
from the molecular weight using LC-MS.
[0206] Calculated value M=423.16, Measured value
(M+H).sup.+=424.3
[0207] Production of Compound No. 137
[0208] The target compound was obtained according to the same
method as Example 3.
[0209] However, ((1-methyl-4-chloroindole-3-yl)methyl)
trimethylammonium iodide was used in the reaction corresponding to
Step 1.
[0210] Confirmation of the compound was carried out by identifying
from the molecular weight using LC-MS.
[0211] Calculated value M=443.11, Measured value
(M+H).sup.+=444.3
Example 5
[0212] Production of Compound No. 244
[0213] The target compound was obtained using the same method as
Example 3. However, 4-cyano-2-nitrotrifluoroacetonitrile was used
as the reagent corresponding to Step 1. In addition, the step in
which the 2-nitroaniline derivative is reduced to an
orthophenylenediamine derivative, and the step in which this is
cyclized to a benzimidazole-2-thiol derivative were carried out
using the methods described below. 46
[0214] 10 ml of ethanol were added to 1.1 g (3.56 mmol) of
((3-benzothiophenyl)methyl)(4-cyano-2-nitrophenyl)amine followed by
the addition of 2.4 g (17.8 mmol) of potassium carbonate. After
replacing the reaction system with nitrogen, 220 mg of 10%
palladium-carbon were added followed by replacing the reaction
system with hydrogen and heating to 60.degree. C.
[0215] After 4 hours and 30 minutes, an additional 220 mg of 10%
palladium-carbon were added followed by replacing the reaction
system with hydrogen and heating to 60.degree. C. 5 hours and 10
minutes after the start of the reaction, the reaction system was
cooled to room temperature. The reaction solution was then filtered
with Celite and concentrated under reduced pressure to obtain 0.93
g of a liquid residue. Continuing, 0.93 g (2.63 mmol) of
((2-benzothiophenyl)methyl)(2-amino-4-m- ethylphenyl)amine were
dissolved in 10 ml of ethanol and 2 ml of water followed by
refluxing after adding 2.1 g (13.3 mmol) of potassium
ethylxanthate. After 11 hours, 12.5 ml of 40% aqueous acetic acid
solution were dropped in. After cooling to room temperature and
concentrating under reduced pressure, the residue was purified by
silica gel column chromatography (hexane:acetone =2:1) to obtain
491.7 mg of
1-((2-benzothiophenyl)methyl)-6-cyanobenzimidazole-2-thiol (yield
of the two steps: 43%). Confirmation of compound no. 244 was
carried out by identifying from the molecular weight using
.sup.1H-NMR and LC-MS.
[0216] Calculated value M=407.08, Measured value
(M+H).sup.+=408.2
[0217] .sup.1H-NMR (400 MHz, CDCl.sub.3) (ppm): 7.94 (s, 1H), 7.76
(dd, 1H), 7.52 (dd, 1H), 7.42 (m, 3H), 7.31 (d, 1H), 7.00 (s, 1H),
5.56 (s, 2H), 3.35 (t, 2H), 2.47 (t, 2H), 2.15 (p, 2H)
Example 6
[0218] The following target compounds were obtained using the same
method as Example 5.
[0219] Production of Compound No. 340
[0220] 4-methyl-2-nitrotrifluoroacetoanilide was used as the
reagent corresponding to Step 1.
[0221] Confirmation of compound no. 340 was carried out by
identifying from the molecular weight using LC-MS.
[0222] Calculated value M=396.10, Measured value
(M+H).sup.+=397.0
[0223] Production of Compound No. 436
[0224] 5-methyl-2-nitrotrifluoroacetoanilide was used as the
reagent corresponding to Step 1.
[0225] Confirmation of compound no. 436 was carried out by
identifying from the molecular weight using LC-MS.
[0226] Calculated value M=396.10, Measured value
(M+H).sup.+=397.0
Example 7
[0227] Production of Compound No. 34 47
[0228] 829 mg (6 mmol) of 2-nitroaniline and 1242 mg (7.8 mmol) of
1-methylindole carboxyaldehyde were dissolved in 20 ml of
tetrahydrofuran followed by the sequential addition of 200 .mu.l of
acetic acid and 5087 mg (24 mmol) of NaBH(OAc).sub.3 and stirring
overnight at room temperature. After adding saturated aqueous
sodium bicarbonate solution, extracting with ethyl acetate and
drying with anhydrous magnesium sulfate, the solvent was distilled
off and the residue was purified by silica gel column
chromatography (hexane:ethyl acetate=95:5) to obtain 264 mg of
((1-methylindole-3-yl)methyl)(2-nitrophenyl)amine (yield: 18%). 264
mg (0.939 mmol) of
((1-methylindole-3-yl)methyl)(2-nitrophenyl)amine were then
dissolved in 10 ml of ethanol followed by the addition of 50 mg
(0.047 mmol) of 10% Pd-C and stirring for 6 hours at room
temperature in a hydrogen atmosphere. After completion of the
reaction, the Pd-C was filtered out and the solvent was distilled
off under reduced pressure to obtain 212 mg of
((1-methylindole-3-yl)methyl)(2-aminophenyl)amine (yield: 90%).
48
[0229] 212 mg (0.845 mmol) of
((1-methylindole-3-yl)methyl)(2-aminophenyl)- amine were dissolved
in 1 ml of pyridine followed by the addition of 1 ml (16.9 mmol) of
carbon disulfide and refluxing for 1 hour in a nitrogen atmosphere.
The solvent was distilled off followed by purification by silica
gel column chromatography (hexane:ethyl acetate=2:1) to obtain 96
mg of 1-((1-methylindole-3-yl)methyl)benzimidazole-2-thiol (yield:
39%). 49
[0230] 12 mg (0.342 mmol) of sodium hydride and 2 ml of
tetrahydrofuran were added to a pre-dried reaction vessel. 50 mg
(0.171 mmol) of
1-((1-methylindole-3-yl)methyl)benzimidazole-2-thiol and 34 l (0.23
mmol) of 4-bromobutanoate ethyl ester were then added to the
reaction vessel followed by stirring for 40 minutes at 60.degree.
C. Water was then added followed by extraction with ethyl acetate.
After drying the ethyl acetate phase with anhydrous magnesium
sulfate, the reaction solution was concentrated under reduced
pressure and the resulting residue was purified by silica gel
column chromatography (hexane:ethyl acetate=3:1) to obtain
4-(1-((1-methylindole-3-yl)methyl)(benzimidazole-2-ylthio)butan-
oate ethyl ester. Continuing, 0.25 ml of 4 M aqueous lithium
hydroxide solution were added to 1 ml of tetrahydrofuran containing
this
4-(1-((1-methylindole-3-yl)methyl)(benzimidazole-2-ylthio)butanoate
ethyl ester and 0.5 ml of methanol. After stirring overnight at
room temperature, 6 M hydrochloric acid was added to stop the
reaction followed by extraction with ethyl acetate. After washing
the ethyl acetate phase with saturated brine, it was dried with
anhydrous magnesium sulfate. The solvent was then distilled off
under reduced pressure to obtain 16 mg (0.042 mmol) of the target
compound (yield: 25%).
[0231] Confirmation of the compound was carried out by identifying
from the molecular weight using LC-MS.
[0232] Calculated value M=379.14, Measured value
(M+H).sup.+=380.2
Example 8
[0233] Production of Compound No. 743 50
[0234] 696 .mu.l (5.0 mmol) of triethylamine and 893 mg (5.0 mmol)
of methyladipochloride were dropped into 10 ml of a chloroform
solution containing 540 mg (5.0 mmol) of orthophenylenediamine
followed by stirring for 12 hours at room temperature. 20 ml of
ethanol and 4 ml of concentrated hydrochloric acid were then added
followed by stirring for 10 hours while heating and refluxing. The
reaction solution was then neutralized using 5 M aqueous sodium
hydroxide solution followed by extraction with ethyl acetate. After
washing with water and concentrating under reduced pressure, the
residue was purified by silica gel column chromatography (ethyl
acetate only) to obtain 359 mg of 5-(benzimidazole-2-yl)pentanoate
ethyl ester (yield: 30%). 51
[0235] 42 mg (0.3 mmol) of potassium carbonate and 103 mg (0.3
mmol) of ((1,4-dimethylindole-3-yl)methyl)trimethylammonium iodide
were added to 2 ml of DMF solution containing 50 mg (0.2 mmol) of
the resulting 5-(benzimidazole-2-yl)pentanoate ethyl ester followed
by stirring for 2 hours at 120.degree. C. The resulting solution
was extracted with dichloromethane, washed with water and
concentrated followed by purification of the residue by column
chromatography (hexane:ethyl acetate=1:2). 5 ml of ethanol and 0.5
ml of 4 M aqueous sodium hydroxide solution were then added to this
followed by stirring for 10 hours at 50.degree. C. and then the
addition of 6 M hydrochloric acid to stop the reaction. The
solution was extracted with chloroform, and after washing with
water and concentrating under reduced pressure, the residue was
purified by silica gel column chromatography
(chloroform:methanol=10:1) to obtain 35 mg of the target compound
(yield of the two steps: 47%). Confirmation of the compound was
carried out by identifying from the molecular weight using
LC-MS.
[0236] Calculated value M=375.19, Measured value
(M+H).sup.+=376.5
Example 9
[0237] 52
[0238] 11.9 ml (1.19 mmol) of 0.1 M aqueous sodium hydroxide
solution were added to 100 ml of an aqueous solution containing 503
mg (1.19 mmol) of the above compound no. 519 followed by stirring
at room temperature. Subsequently, the reaction solution was
freeze-dried to obtain 470 mg (1.05 mmol) of the sodium salt
(yield: 89%).
[0239] .sup.1H-NMR (400 MHz, DMSO-d.sub.6) (ppm): 7.37 (s, 1H),
7.19 (d, 1H, J=8.24 Hz), 7.09-7.01 (m, 2H), 6.80 (d, 1H, J=7.09
Hz), 6.32 (s, 1H), 5.66 (s, 2H), 3.59 (s, 3H), 3.26 (m, 2H), 2.66
(s, 3H), 2.27 (s, 3H), 2.21 (s, 3H), 1.95 (m, 2H), 1.81 (m, 2H)
Example 10
[0240] The compounds indicated below were synthesized using the
respective corresponding substrates according to the same method as
Example 9.
[0241] Sodium Salt of Compound No. 39
[0242] .sup.1H-NMR (270 MHz, DMSO-d.sub.6) (ppm): 7.57 (d, 1H,
J=Hz), 7.28 (d, 1H, J=7 Hz), 7.20 (d, 1H, J=8 Hz), 7.15-7.00 (m,
3H), 6.77 (d, 1H, J=7 Hz), 6.47 (s, 1H), 5.69 (s, 2H), 3.60 (s,
3H), 3.31 (t, 2H, J=7 Hz), 2.61 (s, 3H), 1.99 (t, 2H, J=7 Hz), 1.84
(p, 2H, J=7 Hz)
[0243] Sodium Salt of Compound No. 52
[0244] .sup.1H-NMR (400 MHz, DMSO-d.sub.6) (ppm): 7.97 (d, 1H),
7.91 (d, 1H, J=6.76 Hz), 7.57 (d, 1H, J=7.75 Hz), 7.44-7.38 (m,
3H), 7.30 (s, 1H), 7.12 (m, 2H), 5.63 (s, 2H), 3.33 (m, 2H), 2.03
(m, 2H), 1.87 (m, 2H)
[0245] Sodium Salt of Compound No. 135
[0246] .sup.1H-NMR (400 MHz, DMSO-d.sub.6) (ppm): 7.21-7.00 (m,
4H), 6.79 (d, 1H, J=7.29 Hz), 6.67 (dd, 1H, J=2.43, 8.91 Hz), 6.51
(s, 1H), 5.65 (s, 2H), 3.75 (s, 3H), 3.62 (s, 3H), 3.31 (m, 2H),
2.59 (s, 3H), 1.95 (m, 2H), 1.82 (m, 2H)
[0247] Sodium Salt of Compound No. 532
[0248] .sup.1H-NMR (400 MHz, DMSO-d.sub.6) (ppm): 7.98 (d, 1H,
J=7.42 Hz), 7.90 (d, 1H, J=6.43 Hz), 7.44-7.39 (m, 2H), 7.35 (s,
1H), 7.18 (m, 2H), 5.57 (s, 2H), 3.28 (m, 2H), 2.26 (s, 3H), 2.23
(s, 3H), 1.99 (m, 2H), 1.84 (m, 2H)
Example 10
[0249] Production of
4-(1-((4-methylbenzothiophene-3-yl)methyl)-5-methoxyb-
enzimidazole-2-ylthio)butanoate ethyl ester and
4-(1-((4-methylbenzothioph-
ene-3-yl)methyl)-6-methoxybenzimidazole-2-ylthio)butanoate ethyl
Ester 53
[0250] 539 mg (1.44 mmol) of
4-(5-methoxybenzimidazole-2-ylthio)butanoate ethyl ester were
suspended in 4 ml of toluene followed by the addition of 616 .mu.l
(3.60 mmol) of diisopropylethylamine and 384 mg (1.59 mmol) of
4-methyl-3-(bromomethyl)benzo[b]thiophene and heating at
100.degree. C. After allowing to react overnight, saturated sodium
bicarbonate solution was added followed by extraction with ethyl
acetate. The organic phase was washed with water followed by drying
with magnesium sulfate and concentrating the solvent under reduced
pressure. The resulting residue was purified by silica gel column
chromatography (hexane:ethyl acetate=4:1) to obtain 114 mg of
4-(1-((4-methylbenzothiophene-3-yl)methy-
l)-5-methoxybenzimidazole-2-ylthio)butanoate ethyl ester (yield:
17%) and 68 mg of
4-(1-((4-methylbenzothiophene-3-yl)methyl)-6-methoxybenzimidazol-
e-2-ylthio)butanoate ethyl ester (yield: 10%).
[0251]
4-(1-((4-methylbenzothiophene-3-yl)methyl!-5-methoxybenzimidazole-2-
-ylthio)butanoate ethyl ester
[0252] .sup.1H-NMR (270 MHz, CDCl.sub.3) (ppm): 7.71 (d, 1H, J=7.56
Hz), 7.62 (d, 1H, J=8.64 Hz), 7.30-7.18 (m, 2H), 6.87 (dd, 1H,
J=2.43, 8.64 Hz), 6.61 (d, 1H, J=2.43 Hz), 6.42 (s, 1H), 5.74 (s,
2H), 4.10 (q, 2H, J=7.29 Hz), 3.75 (s, 3H), 3.38 (t, 2H, J=7.29
Hz), 2.89 (s, 3H), 2.45 (t, 2H, J=7.29 Hz), 2.11 (m, 2H), 1.23 (t,
3H, J=7.29 Hz)
[0253]
4-(1-((4-methylbenzothiophene-3-yl)methyl)-6-methoxybenzimidazole-2-
-ylthio)butanoate ethyl Ester
[0254] .sup.1H-NMR (270 MHz, CDCl.sub.3) (ppm): 7.70 (d, 1H, J=8.10
Hz), 7.29-7.17 (m, 3H), 7.02 (d, 1H, J=8.91 Hz), 6.80 (dd, 1H,
J=2.43, 8.91 Hz), 6.40 (s, 1H), 5.74 (s, 2H), 4.11 (q, 2H, J=7.29
Hz), 3.87 (s, 3H), 3.42 (t, 2H, J=7.02 Hz), 2.88 (s, 3H), 2.46 (t,
2H, J=7.29 Hz), 2.10 (m, 2H), 1.23 (t, 3H, J=7.29 Hz)
Example 11
[0255] The following compounds were obtained according to the same
method as Example 10.
[0256]
4-(1-((5-methylbenzothiophene-3-yl)methyl)-5-methoxybenzimidazole-2-
-ylthio)butanoate Ethyl Ester (Yield: 24%)
[0257] .sup.1H-NMR (270 MHz, CDCl.sub.3) (ppm): 7.76 (d, 1H, J=8.10
Hz), 7.62 (s, 1H), 7.58 (d, 1H, J=8.64 Hz), 7.25 (1H), 6.84 (dd,
1H, J=2.43, 8.91 Hz), 6.81 (s, 1H), 6.65 (d, 1H, J=2.16 Hz), 5.47
(s, 2H), 4.11 (q, 2H, J=7.02 Hz), 3.74 (s, 3H), 3.39 (t, 2H, J=7.02
Hz), 2.51 (s, 3H), 2.47 (t, 2H, J=7.56 Hz), 2.11 (m, 2H), 1.24 (t,
3H, J=7.02 Hz)
4-(1-((5-methylbenzothiophene-3-yl)methyl)-6-methoxybenzimidazole-2-ylthi-
o)butanoate ethyl ester
[0258] (Yield: 18%)
[0259] .sup.1H-NMR (270 MHz, CDCl.sub.3) (ppm): 7.75 (d, 1H, J=8.10
Hz), 7.60 (s, 1H), 7.26-7.22 (m, 2H), 7.04 (d, 1H, J=8.91 Hz), 6.83
(s, 1H), 6.78 (dd, 1H, J=2.43, 8.91 Hz), 5.47 (s, 2H), 4.12 (q, 2H,
J=7.02 Hz), 3.84 (s, 3H), 3.43 (t, 2H, J=7.29 Hz), 2.50 (s, 3H),
2.48 (t, 2H, J=7.29 Hz), 2.12 (m, 2H), 1.24 (t, 3H, J=7.02 Hz)
Example 12
[0260] Production of
4-(1-((4-methylbenzothiophene-3-yl)methyl)-5-methoxyb-
enzimidazole-2-ylthio)butanoic acid (Compound No. 154) 54
[0261] 84.7 mg (0.186 mmol) of the
4-(1-((4-methylbenzothiophene-3-yl)meth-
yl)-5-methoxybenzimidazole-2-ylthio)butanoate ethyl ester obtained
in Example 10 were dissolved in a mixed solvent of 1 ml of THF and
1 ml of ethanol followed by the addition of 1 ml of 1 M aqueous
sodium hydroxide solution and stirring for 1 hour at 40.degree. C.
Following completion of the reaction, 1.5 ml of 1 M hydrochloric
acid were added followed by stirring for 30 minutes at room
temperature. The resulting precipitate was filtered, washed with
water, washed with ethanol and then dried to obtain 54.9 mg of the
target compound (yield: 69%).
[0262] LC-MS:
[0263] Calculated value M=426.11, Measured value
(M+H).sup.+=427.2
[0264] .sup.1H-NMR (270 MHz, DMSO-d.sub.6) (ppm): 7.80 (d, 1H,
J=7.29 Hz), 7.60 (d, 1H, J=8.91 Hz), 7.31-7.20 (m, 3H), 6.95 (dd,
1H, J=2.16, 8.91 Hz), 6.53 (s, 1H), 5.94 (s, 2H), 3.73 (s, 3H),
3.37 (t, 2H, J=7.29 Hz), 2.86 (s, 3H), 2.34 (t, 2H, J=7.29 Hz),
1.90 (m, 2H)
Example 13
[0265] The following compounds were synthesized according to the
same method as Example 12.
[0266]
4-(1-((4-methylbenzothiophene-3-yl)methyl)-6-methoxybenzimidazole-2-
-ylthio)butanoic Acid (Compound No. 1114)
[0267] Yield: 60%
[0268] LC-MS:
[0269] Calculated value M=426.11, Measured value
(M+H).sup.+=427.2
[0270] .sup.1H-NMR (270 MHz, DMSO-d.sub.6) (ppm): 7.78 (d, 1H,
J=7.83 Hz), 7.52 (d, 1H, J=8.91 Hz), 7.34-7.17 (m, 3H), 6.77 (dd,
1H, J=2.34, 8.91 Hz), 6.37 (s, 1H), 5.83 (s, 2H), 3.78 (s, 3H),
3.32 (t, 2H, J=7.29 Hz), 2.82 (s, 3H), 2.34 (t, 2H, J=7.56 Hz),
1.93 (m, 2H)
[0271] In this case however, 1 M hydrochloric acid was added
following completion of the reaction followed by extraction with
chloroform and washing with water. Drying was then performed with
magnesium sulfate followed by concentrating the solvent under
reduced pressure and drying to obtain the target compound.
4-(1-((5-methylbenzothiophene-3-yl)methyl)-
-5-methoxybenzimidazole-2-ylthio)butanoic acid (Compound No.
152)
[0272] Yield: 63%
[0273] LC-MS:
[0274] Calculated value M=426.11, Measured value
(M+H).sup.+=426.8
[0275] .sup.1H-NMR (270 MHz, DMSO-d.sub.6) (ppm): 7.88 (d, 1H,
J=8.64 Hz), 7.76 (s, 1H), 7.58 (d, 1H, J=8.64 Hz), 7.28-7.24 (m,
3H), 6.94 (dd, 1H, J=2.16, 8.64 Hz), 5.72 (s, 2H), 3.74 (s, 3H),
3.40 (t, 2H, J=7.29 Hz), 2.42 (s, 3H), 2.36 (t, 2H, J=7.29 Hz),
1.92 (m, 2H)
[0276]
4-(1-((5-methylbenzothiophene-3-yl)methyl)-6-methoxybenzimidazole-2-
-ylthio)butanoic Acid (Compound No. 1112)
[0277] Yield: 79%
[0278] LC-MS:
[0279] Calculated value M=426.11, Measured value
(M+H).sup.+=427.0
[0280] .sup.1H-NMR (270 MHz, DMSO-d.sub.6) (ppm): 7.87 (d, 1H,
J=8.10 Hz), 7.71 (s, 1H), 7.47 (d, 1H, J=8.91 Hz), 7.24 (m, 2H),
7.17 (d, 1H, J=2.16 Hz), 6.84 (dd, 1H), 5.64 (s, 2H), 3.77 (s, 3H),
3.38 (t, 2H, J=7.02 Hz), 2.41 (s, 3H), 2.37 (t, 2H, J=7.56 Hz),
1.95 (m, 2H)
Example 14
[0281] Production of HCl Salt of Compound No. 532 55
[0282] 1.5 ml of 4 M hydrochloric acid/dioxane solution were added
to 50 mg (0.122 mmol) of compound no. 532 followed by stirring at
100.degree. C. Following completion of the reaction, the reaction
solution was concentrated under reduced pressure to obtain 53 mg
(1.05 mmol) of the target compound (yield: 97%).
[0283] .sup.1H-NMR (270 MHz, DMSO-d.sub.6) (ppm): 8.00 (m, 1H),
7.89 (m, 1H), 7.52 (m, 2H), 7.45-7.42 (m, 2H), 7.32 (s, 1H), 5.78
(s, 2H), 3.48 (t, 2H, J=7.42 Hz), 2.37 (m, 2H), 2.34 (s, 3H), 2.30
(s, 3H), 1.92 (t, 2H, J=7.09 Hz)
Example 15
[0284] Production of HCl Salt of Compound No. 56
[0285] The target compound was obtained according to the same
method as Example 14.
[0286] .sup.1H-NMR (270 MHz, DMSO-d.sub.6) (ppm): 7.87 (d, 1H,
J=8.08 Hz), 7.74 (s, 1H), 7.66 (d, 1H, J=6.76 Hz), 7.58 (d, 1H,
J=8.74 Hz), 7.26 (m, 4H), 5.70 (s, 2H), 3.45 (t, 2H, J=7.26 Hz),
2.42 (s, 3H), 2.39 (t, 2H, J=7.26 Hz), 1.98 (m, 2H)
Example 16
[0287] Preparation of Recombinant Human Mast Cell Chymase
[0288] Recombinant human mast cell chymase was prepared in
accordance with the report of Urata, et al. (Journal of Biological
Chemistry, Vol. 266, p. 17173 (1991)). Namely, human mast cell
chymase was purified by heparin sepharose (Pharmacia) from a
culture supernatant of insect cells (Th5) infected with recombinant
baculovirus containing cDNA coding for human mast cell chymase.
Moreover, after activating in accordance with the report of
Murakami, et al. (Journal of Biological Chemistry, Vol. 270, p.
2218 (1995)), the human mast cell chymase was purified with heparin
sepharose to obtain active human mast cell chymase.
Example 17
[0289] Measurement of Inhibition of Enzyme Activity of Recombinant
Human Mast Cell Chymase
[0290] After adding 2 l of DMSO solution containing a compound of
the present invention to 50 l of Buffer A (0.5-3.0 M NaCl, 50 mM
Tris-HCl, pH 8.0) containing 1-5 ng of the active human mast cell
chymase obtained in Example 16, 50 .mu.l of Buffer A containing 0.5
mM succinyl-alanyl-histidyl-prolyl-phenylalanylparanitroanilide
(Bacchem) as substrate were added and allowed to react for 5
minutes at room temperature. The changes over time in absorbance at
405 nm were measured to investigate inhibitory activity.
[0291] As a result, compound nos. 39, 56, 58, 59, 63, 148, 154,
519, 532, 534, 536, 538, 615, 1112 and 1114 were observed to
demonstrate inhibitory activity of IC.sub.50=1 nM to less than 10
nM, while compound nos. 34, 38, 41, 42, 52, 54, 135, 137, 152, 244,
340, 436, 514, 521 and 628 were observed to demonstrate inhibitory
activity of IC.sub.50=10 nM to 100 nM.
[0292] As has been shown above, the benzimidazole derivatives of
the present invention exhibit potent chymase inhibitory activity.
Thus, the benzimidazole derivatives of the present invention were
clearly demonstrated to be human chymase activity inhibitors that
can be applied clinically for use in the prevention and/or
treatment of various diseases involving human chymase.
Example 18
[0293] Production of Tablets
[0294] Tablets were produced having the individual tablet
composition shown below.
3 Compound No. 39 50 mg Lactose 230 mg Potato starch 80 mg
Polyvinylpyrrolidone 11 mg Magnesium stearate 5 mg
[0295] The compound of the present invention (compound of the
examples), lactose and potato starch were mixed followed by
uniformly wetting with a 20% ethanol solution of
polyvinylpyrrolidone, passing through a 20 mesh sieve, drying at
45.degree. C. and again passing through a 15 mesh sieve. The
granules obtained in this manner were then mixed with magnesium
stearate and compressed into tablets.
Example 19
[0296] Measurement of Blood Concentration During Administration by
Intragastric Forced Feeding to Rats
[0297] The compounds indicated with the above compound nos. 39, 52
and 244 were administered by intragastric forced feeding to male SD
rats while fasting at a dose of 30 mg/kg, after which blood samples
were collected immediately after administration and at 30 minutes
and 1, 2 and 4 hours after administration. Following collection of
blood samples, where samples were immediately separated into serum
components, the compound of the present invention was extracted by
ordinary solid phase extraction methods, and the resulting samples
were analyzed by HPLC using an ODS column (32%
acetonitrile-water-0.05% TFA was used for the mobile phase for
compound nos. 52 and 244, while 47% acetonitrile-water-10 mM
ammonium acetate buffer (pH 4.0) was used for the mobile phase for
compound no. 39) followed by measurement of the amount of the
unchanged form. Those results are shown in the table below.
4 Compound No. After 30 min. (.mu.g/ml) After 4 hr. (.mu.g/ml) 52
60.5 12.7 244 16.5 8.9 39 16.1 6.3
[0298] On the basis of the above results, the compounds of the
present invention were rapidly absorbed after administration, and
blood concentrations of the unchanged form shown in the table were
measured after 30 minutes. Moreover, although blood concentrations
decreased gradually until 4 hours after administration, a
considerable amount of the unchanged forms could still be confirmed
even at 4 hours after administration. Thus, the compounds of the
present invention were determined to be a group of compounds having
superior pharmacokinetic properties. The pharmacokinetic properties
of the group of compounds in which A is
--CH.sub.2CH.sub.2CH.sub.2-- are particularly superior.
Example 20
[0299]
5 In Vitro Metabolism Test Using Liver Microsomes (Ms) Measurement
Method: * Reaction Solution Composition and Reaction Conditions
Composition and Procedure Composition Reagent name Final conc.
Comments Reconstruction Buffer Phosphate 0.1 M Reaction system
Composition buffer (pH solution 7.4) volume: 0.5 mL Chelating EDTA
1.0 mM agent NADPH Magnesium 3.0 mM generation chloride system G6P
5.0 mM G6PDH 1.0 IU Enzyme Liver 1.0 mg/mL microsomes Substrate
Substrate 5.0 .mu.M (evaluation compound) Reaction NADPH 1.0 mM
initiator Reaction conditions 37.degree. C., incubation (water
bath, shaking) , reaction times: 0, 2, 5, 10 and 30 min. Reaction
terminator Acetonitrile Equal to 3 (extraction liquid) volumes of
reaction solution Deproteinization Sampling of supernatant after
centrifuging for 10 min. at 3000 rpm, removal of solvent with
evaporator Redissolution liquid Redissolution with HPLC mobile
phase used for analysis Analysis Detection of peak of unchanged
form by HPLC using UV detector * MR Calculation Method
[0300] The metabolic rate was determined from the decrease in the
amount of the unchanged form at each reaction time and the reaction
time based on assigning a value of 100% to the amount of the
unchanged form at the initial concentration (reaction time: 0
minutes), and the metabolic rate at the time the metabolic rate
reached a maximum was evaluated as the MR value.
MR=(substrate concentration at reaction time: 0 min.-substrate
concentration after reaction).div.reaction time.div.protein
concentration (nmol/min./mg protein)
[0301] These methods were used to obtain the measurement results
indicated below.
6 Percentage of substrate remaining Compound No. MR after 30 min.
(%) 34 0.260 60.3 38 0.329 29.8 39 0 80.1 41 0.129 73.9 52 0.331
47.5 56 0.111 41.2 58 0.048 72.3 135 0.097 55.2 244 0.211 57.9 514
0.087 48.7 519 0.102 52.9 521 0.088 61.1 532 0.277 36.2 534 0.102
63.0 536 0.131 56.3 615 0.159 62.3
[0302] According to the above results, the compounds of the present
invention are a group of metabolically stable compounds. The group
of compounds in which A is --CH2CH2CH2-- was determined to be a
group of particularly metabolically stable compounds.
INDUSTRIAL APPLICABILITY
[0303] The benzimidazole derivatives of the present invention or
their medically allowed salts exhibit potent human chymase
inhibitory activity. Thus, said benzimidazole derivatives or their
medically allowed salts can be used as preventive and/or
therapeutic agents that can be applied clinically as human chymase
inhibitors for inflammatory diseases, allergic diseases,
respiratory diseases, cardiovascular diseases or bone and cartilage
metabolic diseases.
* * * * *